586 The impact of the pattern of recurrence on post-relapse survival according to surgicat timing in patients with advanced ovarian cancer
E. Ovarian cancer  Martina Aida  Angelika  France  Poster session A + ePoster  PA-044  28 Oct  08:00-18:00  Poster Area (Exhibition Area)

589 The effect of major postoperative complications on recurrence and long-term survival after cytoreductive surgery for ovarian cancer
E. Ovarian cancer  Martina Aida  Angelika  France  Poster session A + ePoster  PA-045  28 Oct  08:00-18:00  Poster Area (Exhibition Area)

609 Factors related to grade 3a Cavan-Sonde Complications and Delayed Time to Chemotherapy after Cytoreductive Surgery for Advanced Stage Ovarian Cancer: A Prospective Cohort Study
E. Ovarian cancer  Helena van Doorn  Netherlands  Poster session A + ePoster  PA-046  28 Oct  08:00-18:00  Poster Area (Exhibition Area)

624 DNA-LEAK: Prognostic score for colorectal anastomotic leakage in patients undergoing ovarian cancer surgery
E. Ovarian cancer  Victor  Lago  Spain  Poster session A + ePoster  PA-047  28 Oct  08:00-18:00  Poster Area (Exhibition Area)

660 Characterisation of Extended Treatment Benefit From Three Phase 1 and 3 Clinical Trials Examining Patients With Folate Receptor Alpha-Positive Recurrent Ovarian Cancer Treated With Single-Agent Primary and Interval Debunking surgery in advanced ovarian cancer: Real-World Clinical Outcomes of Patients in 1st line setting. Analysis from the French national FRM: Ovar 2014 database
E. Ovarian cancer  Ana  Otkin  Spain  Poster session A + ePoster  PA-048  28 Oct  08:00-18:00  Poster Area (Exhibition Area)

703 The role of Minimaly Invasive Secondary Cyto reduction in Recurrent Ovarian Cancer Patients.
E. Ovarian cancer  Camilla  Coat  Italy  Poster session A + ePoster  PA-050  28 Oct  08:00-18:00  Poster Area (Exhibition Area)

722 Phase 2 study assessing the efficacy of adding Atezolizumab (Cetuximab) to chemotherapy in subjects with platinum-resistant ovarian cancer
E. Ovarian cancer  David  Miller  United States  Poster session A + ePoster  PA-051  28 Oct  08:00-18:00  Poster Area (Exhibition Area)

792 Outcomes following Stereotactic Radiotherapy for brain metastasis in ovarian cancer patients
E. Ovarian cancer  Shira  Peleg  Hasson  United Kingdom  Poster session A + ePoster  PA-052  28 Oct  08:00-18:00  Poster Area (Exhibition Area)

800 AGO-OVAB 27: Window of opportunity: proof-of-concept, non-randomized, open-label phase II trial of Olaparib given alone or in combination with Durvalumab prior to primary debulking surgery
E. Ovarian cancer  Frederik  Marmel  Germany  Poster session A + ePoster  PA-053  28 Oct  08:00-18:00  Poster Area (Exhibition Area)

817 Comparison of surgeon’s intraoperative assessment of residual tumor and postoperative findings on computed tomography in patients with advanced stage epithelial ovarian, tubal or peritoneal ovarian cancer
E. Ovarian cancer  Inge  Peters  Italy  Poster session A + ePoster  PA-054  28 Oct  08:00-18:00  Poster Area (Exhibition Area)

833 FOXK1 mutation detection in circulating tumor DNA of adult granulosa cell tumors as a potential biomarker for disease monitoring from the randomised ALIENOR trial, a GIMECO study
E. Ovarian cancer  Sibelle  Treil  France  Poster session A + ePoster  PA-056  28 Oct  08:00-18:00  Poster Area (Exhibition Area)

835 AGO-OVAB 2.34: MIRCOV: A Randomized phase III trial of menotecumab sorafenib (MIRNOB3), in folate receptor alpha (FRa) high recurrent ovarian cancer eligible for platinum-based therapy
E. Ovarian cancer  Fabian  Tidblust  Germany  Poster session A + ePoster  PA-057  28 Oct  08:00-18:00  Poster Area (Exhibition Area)

840 Prognostic impact of molecular profiles and molecular signatures in clear cell ovarian cancer.
E. Ovarian cancer  Tine  Schmick  Denmark  Poster session A + ePoster  PA-058  28 Oct  08:00-18:00  Poster Area (Exhibition Area)

850 Benefit of bevacizumab according to CA125 decrease kinetic in first-line high grade serous ovarian carcinoma (HGSOC) patients in real-life setting
E. Ovarian cancer  Benoit  You  France  Poster session A + ePoster  PA-059  28 Oct  08:00-18:00  Poster Area (Exhibition Area)

877 Epidemiological study on oncological outcome of patients with incidental findings of borderline ovarian tumors or ovarian cancer treated with a two-step surgical procedure
E. Ovarian cancer  Franziska  Siegenthaler  Switzerland  Poster session A + ePoster  PA-060  28 Oct  08:00-18:00  Poster Area (Exhibition Area)

891 Preoperative assessment of non-resectability in patients with ovarian cancer using imaging (ISAAK study) - an interim analysis
E. Ovarian cancer  Patricia  Pinto  Czech Republic  Poster session A + ePoster  PA-061  28 Oct  08:00-18:00  Poster Area (Exhibition Area)

906 Acid ceramidase (ASAH1) expression is associated with improved progression- and overall survival in high-grade serous ovarian cancer patients
E. Ovarian cancer  Lars  Hanker  Germany  Poster session A + ePoster  PA-063  28 Oct  08:00-18:00  Poster Area (Exhibition Area)

909 AGO-OVAB 28 / ENDOT exv.: Niraparib vs irinotecan in combination with bevacizumab in patients with carboplatin-taxane based chemotherapy in advanced ovarian cancer (multicentre)
E. Ovarian cancer  Florian  Heitz  Germany  Poster session A + ePoster  PA-064  28 Oct  08:00-18:00  Poster Area (Exhibition Area)

913 Clinical performance evaluation of a novel deep learning solution for homologous recombination deficiency detection
E. Ovarian cancer  Adrien  Buisson  France  Poster session A + ePoster  PA-065  28 Oct  08:00-18:00  Poster Area (Exhibition Area)

928 Reprogramming of patient-derived HGSOC organoids following carboplatin treatment links stemness potential and mechanisms of resistance
E. Ovarian cancer  Mirjana  Kessler  Germany  Poster session A + ePoster  PA-066  28 Oct  08:00-18:00  Poster Area (Exhibition Area)

937 Ercaparab Maintenance after Bevacizumab Maintenance Following Carboplatin based chemotherapy in primary Ovarian Cancer
E. Ovarian cancer  Elena-Ioana  Braicu  Germany  Poster session A + ePoster  PA-067  28 Oct  08:00-18:00  Poster Area (Exhibition Area)

944 Real-world safety, baseline characteristics and first-year therapy management in patients with BRCA/BRCA-mutated advanced ovarian cancer treated with olaparib tablets in the first-line treatment settings
E. Ovarian cancer  Domenica  Lorusso  Italy  Poster session A + ePoster  PA-068  28 Oct  08:00-18:00  Poster Area (Exhibition Area)

956 Treatment patterns and outcomes after progression on poly-ADP ribose polymerase inhibitor maintenance therapy
E. Ovarian cancer  Giulia  Tascia  Italy  Poster session A + ePoster  PA-070  28 Oct  08:00-18:00  Poster Area (Exhibition Area)

1014 Incidence of pelvic high-grade serous carcinoma after isolated STK: A systematic review of the literature
E. Ovarian cancer  Marco  Battista  Germany  Poster session A + ePoster  PA-071  28 Oct  08:00-18:00  Poster Area (Exhibition Area)

1074 AGO-OVAB 2.29 [ENGT OV-34]: Alizorecab in combination with Carboplatin and Chemotherapy vs Bevacizumab and Chemotherapy in recurrent ovarian cancer
E. Ovarian cancer  Philipp  Harter  Germany  Poster session A + ePoster  PA-072  28 Oct  08:00-18:00  Poster Area (Exhibition Area)

1088 Ultimate response after 3 cycles of chemotherapy as a promising marker of chemosensitivity: an ancillary analysis of the GINECO ENGCT Ov34 (ENGCT-ov34) trial
E. Ovarian cancer  Claire  Falandry  France  Poster session A + ePoster  PA-073  28 Oct  08:00-18:00  Poster Area (Exhibition Area)

1103 Prediction of incomplete cytoreduction in primary debulking surgery of advanced stage ovarian cancer patients: Usefulness of the entire peritoneal cancer index (PCI) versus exclusive assessment of small granulosa cell tumors as a potential biomarker for disease monitoring in ovarian cancer patients
E. Ovarian cancer  Angela  Rathner  Germany  Poster session A + ePoster  PA-074  28 Oct  08:00-18:00  Poster Area (Exhibition Area)

1110 Impact of comorbidities, postoperative complications and center volume on overall survival in a real-life cohort of 29,870 ovarian cancer patients
E. Ovarian cancer  Floriane  Jochum  France  Poster session A + ePoster  PA-075  28 Oct  08:00-18:00  Poster Area (Exhibition Area)

1111 ECGA as a valuable tool to improve physician competence regarding identification of patients and selection of treatment for newly diagnosed advanced ovarian cancer
E. Ovarian cancer  Yelena  Parada  United Kingdom  Poster session A + ePoster  PA-076  28 Oct  08:00-18:00  Poster Area (Exhibition Area)

1238 Stereotactic Ablative Radiotherapy in Oligometastatic Gynecologic Malignancies
7. Palliative care  Ahmed  El Medr  United Kingdom  Poster session A + ePoster  PA-079  28 Oct  08:00-18:00  Poster Area (Exhibition Area)
1174 Role of adjuvant therapy in intermediate-risk cervical cancer patients - SCARMY study sub-analysis.
1. Cervical cancer
David Cibula
Czech Republic
Poster session B + ePoster
PB-011
29 Oct 08:00-18:00 Poster Area (Exhibition Area)

1217 Cervical cancer: Intraoperative and postoperative complications: minimally invasive versus open radical hysterectomy in early cervical cancer
1. Cervical cancer
Felix Boria
Spain
Poster session B + ePoster
PB-012
29 Oct 08:00-18:00 Poster Area (Exhibition Area)

1253 LNG-IUS Trial: demonstrates that Clinical Regression of High-Grade Cervical Intraepithelial Neoplasia Is Associated With Absence of FAM19A4(miR124-2 DNA Methylation
1. Cervical cancer
Nienke van Trommel
Netherlands
Poster session B + ePoster
PB-013
29 Oct 08:00-18:00 Poster Area (Exhibition Area)

1257 ICG-mapped sentinel lymph-node biopsy in endometrial cancer: a sub-analysis of the SCARMY study.
1. Cervical cancer
David Cibula
Czech Republic
Poster session B + ePoster
PB-014
29 Oct 08:00-18:00 Poster Area (Exhibition Area)

1263 Poster I randomized BIOG-1005 that comparing alestalubin in combination with docetaxel versus docetaxel alone in second- line or later recurrent cervical cancer
1. Cervical cancer
Lisa Fujita
The Netherlands
Poster session B + ePoster
PB-015
29 Oct 08:00-18:00 Poster Area (Exhibition Area)

1301 The impact of hospital surgical volume on survival in early stage cervical cancer treated with radical hysterectomy; a sub-analysis of the SCARMY study.
1. Cervical cancer
Niccolò Bizzarri
Italy
Poster session B + ePoster
PB-016
29 Oct 08:00-18:00 Poster Area (Exhibition Area)

577 Prognostic Significance of Signs for Metastatic Involvement of Lymph Nodes in Cervical Cancer According to Magnetic Resonance Imaging
2. Diagnostics
Olga Matylevich
Belarus
Poster session B + ePoster
PB-017
29 Oct 08:00-18:00 Poster Area (Exhibition Area)

610 Radiomics and transvoual ultrasound in adrenal masses: is the next future of diagnostics here?
2. Diagnostics
Valentia Chiappa
Italy
Poster session B + ePoster
PB-018
29 Oct 08:00-18:00 Poster Area (Exhibition Area)

767 Machine learning to implement the accuracy of magnetic resonance imaging (MRI) in the detection of lymph node metastasis in patients with locally advanced cervical cancer treated with neoadjuvant chemotherapy.
2. Diagnostics
Gennaro Cormio
Italy
Poster session B + ePoster
PB-020
29 Oct 08:00-18:00 Poster Area (Exhibition Area)

872 Peritoneal carcinose urine needle biopsy with microscopics and array-CGH analyses in patients with suspicious myometrial tumors on MRI: a prospective study
2. Diagnostics
Enora Laas
France
Poster session B + ePoster
PB-021
29 Oct 08:00-18:00 Poster Area (Exhibition Area)

899 Electrode biosips coupled to isothermal amplification LAMP technique in diagnostics of cervical precancer
2. Diagnostics
Martin Bartosik
Czech Republic
Poster session B + ePoster
PB-022
29 Oct 08:00-18:00 Poster Area (Exhibition Area)

1161 The impact of oophorectomy on survival from breast cancer in patients with CHEK2 mutations
1. Cervical cancer
Juan C. Tomizaca-
Szwiec
Poland
Poster session B + ePoster
PB-023
29 Oct 08:00-18:00 Poster Area (Exhibition Area)

1403 Comparison of ADNEXmodel, O-RADS and the combined OOTA Simple Rules with Simple Rules Risk assessment and Simple Rules with ADNEX model in discriminating between benign and malignant cervical lesions
3. Endometrial cancer
Giulia Spagnol
Italy
Poster session B + ePoster
PB-024
29 Oct 08:00-18:00 Poster Area (Exhibition Area)

994 Evaluation of One Step Nuclease Acid Amplification (OSNA) method for rapid detection of lymph node metastases in women with endometrial cancer
3. Endometrial cancer
Eleonora La Fera
Italy
Poster session B + ePoster
PB-025
29 Oct 08:00-18:00 Poster Area (Exhibition Area)

995 Independent prognostic significance of subcutaneous lymphovascular space invasion (LVSI) in a consecutive series of primary LVSI-positive endometrial carcinoma (EC)
3. Endometrial cancer
Stefan Kemnoss
Germany
Poster session B + ePoster
PB-026
29 Oct 08:00-18:00 Poster Area (Exhibition Area)

1009 Immuno-related endpoints in patients with advanced or recurrent endometrial cancer treated with dostarlimab in the GARNET study
3. Endometrial cancer
Anna Tinker
Canada
Poster session B + ePoster
PB-027
29 Oct 08:00-18:00 Poster Area (Exhibition Area)

1052 Comparative immuno-related endpoints in women with locally advanced cervical cancer and no adjuvant treatment: no relationus tumor cells (ITC) have an effect on recurrence? An international multi-institutional comparative study between ITC and node-
3. Endometrial cancer
Giuseppe Cucinella
United States
Poster session B + ePoster
PB-028
29 Oct 08:00-18:00 Poster Area (Exhibition Area)

1106 Laparoscopic versus open abdominal hysterectomy in endometrial cancer patients: Analysis of outcome according to risk group
3. Endometrial cancer
Valentina Auletta
Germany
Poster session B + ePoster
PB-030
29 Oct 08:00-18:00 Poster Area (Exhibition Area)

1181 Survival outcomes and recurrence patterns of laparotomy versus minimal invasive surgery in women with intermediate- and high-risk uterine cancer at a tertiary referral center
3. Endometrial cancer
Perinle Bjerre Trent
Norway
Poster session B + ePoster
PB-031
29 Oct 08:00-18:00 Poster Area (Exhibition Area)

1196 Secondary Cytoexeructive Surgery in Endometrial Cancer Recurrence: How to triage patients towards surgery, a Multicenter Study
3. Endometrial cancer
Virginia Vargiu
Italy
Poster session B + ePoster
PB-032
29 Oct 08:00-18:00 Poster Area (Exhibition Area)

1250 The MULTISENT study: A Multicenter study about the Sentinel lymph Node biopsy in clinical stage I and II Endometrial Cancer
3. Endometrial cancer
Natalia R. Gomez-
Gonzalez
Spain
Poster session B + ePoster
PB-033
29 Oct 08:00-18:00 Poster Area (Exhibition Area)

1289 Understanding clinical and pathological heterogeneity of endometrial cancer with no specific molecular profile (NSMPC)
3. Endometrial cancer
Luigi Antonio De Vitiis
Italy
Poster session B + ePoster
PB-034
29 Oct 08:00-18:00 Poster Area (Exhibition Area)

1297 A subgroup analysis of response rate by patient characteristics in patients with endometrial cancer receiving monotherapy dostarlimab in the GARNET trial
3. Endometrial cancer
Ana Odkin
Spain
Poster session B + ePoster
PB-035
29 Oct 08:00-18:00 Poster Area (Exhibition Area)

1475 Impact of molecular profiling on endometrial cancer staging: towards a personalized approach
3. Endometrial cancer
Silvia Cabrera
Spain
Poster session B + ePoster
PB-036
29 Oct 08:00-18:00 Poster Area (Exhibition Area)

1534 iCG-mapped sentinel lymph-node biopsy in endometrial cancer: analysis of surgeons' learning process
3. Endometrial cancer
Migle Gedgaudait
Lithuania
Poster session B + ePoster
PB-037
29 Oct 08:00-18:00 Poster Area (Exhibition Area)

1569 Molecular profile in endometrial carcinoma: can we predict the lymph node status?
3. Endometrial cancer
Ana Luzarraga
Spain
Poster session B + ePoster
PB-038
29 Oct 08:00-18:00 Poster Area (Exhibition Area)

1593 Major determinants of survival in recurrent endometrial cancer: The role of secondary cytoreductive surgery and relapse pattern. A Multicenter Study
3. Endometrial cancer
Virginia Vargiu
Italy
Poster session B + ePoster
PB-039
29 Oct 08:00-18:00 Poster Area (Exhibition Area)

1688 Evaluation of the impact of HRT on endometrial thickness and the diagnosis of endometrial cancer
3. Endometrial cancer
Nataliah D'Souza
United Kingdom
Poster session B + ePoster
PB-040
29 Oct 08:00-18:00 Poster Area (Exhibition Area)

156 Minimally invasive versus open abdominal approaches for early-stage cervical and endometrial cancer: a meta-analysis of prospective randomised controlled trials (RCTs)
5. Miscellaneous
Ines Ongenda
United Kingdom
Poster session B + ePoster
PB-041
29 Oct 08:00-18:00 Poster Area (Exhibition Area)

165 Diagnostic value of transperitoneal abdomen plane (TAPP) shock versus placebo after midline laparotomy in gynecologic oncology: a double-blind randomized trial
5. Miscellaneous
Laurence Bernard
United States
Poster session B + ePoster
PB-042
29 Oct 08:00-18:00 Poster Area (Exhibition Area)

607 How long should patients stay fasting? A multicentric prospective survey on the perioperative fasting in 524 Patients conducted by the IAGO study group
5. Miscellaneous
Maxmillian Beck
Germany
Poster session B + ePoster
PB-043
29 Oct 08:00-18:00 Poster Area (Exhibition Area)

638 Tomamarker with multimodal immunomodulation in chemotherapy-pretreated cervical, endometrial, and uterine cancer the PRIMMG phase II trial
5. Miscellaneous
Emiel De Jaeghere
Belgium
Poster session B + ePoster
PB-044
29 Oct 08:00-18:00 Poster Area (Exhibition Area)

744 Repurposing screening to reduce the risk of vital reactivation in gynecologic oncology patients receiving chemotherapy at a regional tertiary cancer centre: a quality improvement initiative
5. Miscellaneous
Sarah Mah
Canada
Poster session B + ePoster
PB-045
29 Oct 08:00-18:00 Poster Area (Exhibition Area)
6. Ovarian cancer
Poster session B +
08:00-18:00
29 Oct
Poster session B +
08:00-18:00
Italy

Sentinel-node biopsy in early-stage ovarian cancer: preliminary results of a prospective multicentre study
E. Ovarian cancer
Simpson
Monterrey Macias
France
Poster session B +
ePoster
PB-076
29 Oct
08:00-18:00
Poster Area (Exhibition Area)

Laparoscopic cytoreduction and complex debulking surgery in advanced low grade serous ovarian cancer: a secondary analysis of the OMA trial
E. Ovarian cancer
Kirsch
Velji
United Kingdom
Poster session B +
ePoster
PB-083
29 Oct
08:00-18:00
Poster Area (Exhibition Area)

E. Ovarian cancer
Berton
Lima
Italy
Poster session B +
ePoster
PB-077
29 Oct
08:00-18:00
Poster Area (Exhibition Area)

Selection of preexisting BRCA1/2-proficient tumor cells in BRCA1/2-mutated ovarian carcinomas treated by neoadjuvant chemotherapy
E. Ovarian cancer
Eriksson
Barakat
Sweden
Poster session B +
ePoster
PB-078
29 Oct
08:00-18:00
Poster Area (Exhibition Area)

Minimally invasive versus open pelvic exenteration in gynecological malignancies: a propensity-matched survival analysis
E. Ovarian cancer
Eriksson
Nicolò
Germany
Poster session B +
ePoster
PB-081
29 Oct
08:00-18:00
Poster Area (Exhibition Area)

The impact of the new RCOG 2019 curriculum and COVID-19 pandemic on Gynaecological training amongst the Specialist Registrars in the UK
E. Ovarian cancer
Velji
Barakat
United Kingdom
Poster session B +
ePoster
PB-079
29 Oct
08:00-18:00
Poster Area (Exhibition Area)

Selection of preexisting BRCA1/2-proficient tumor cells in BRCA1/2-mutated ovarian carcinomas treated by neoadjuvant chemotherapy
E. Ovarian cancer
Eriksson
Barakat
Sweden
Poster session B +
ePoster
PB-078
29 Oct
08:00-18:00
Poster Area (Exhibition Area)

Minimally invasive versus open pelvic exenteration in gynecological malignancies: a propensity-matched survival analysis
E. Ovarian cancer
Eriksson
Nicolò
Germany
Poster session B +
ePoster
PB-081
29 Oct
08:00-18:00
Poster Area (Exhibition Area)

E. Ovarian cancer
Berton
Lima
Italy
Poster session B +
ePoster
PB-077
29 Oct
08:00-18:00
Poster Area (Exhibition Area)

Sentinel-node biopsy in early-stage ovarian cancer: preliminary results of a prospective multicentre study
E. Ovarian cancer
Simpson
Monterrey Macias
France
Poster session B +
ePoster
PB-076
29 Oct
08:00-18:00
Poster Area (Exhibition Area)

Laparoscopic cytoreduction and complex debulking surgery in advanced low grade serous ovarian cancer: a secondary analysis of the OMA trial
E. Ovarian cancer
Kirsch
Velji
United Kingdom
Poster session B +
ePoster
PB-083
29 Oct
08:00-18:00
Poster Area (Exhibition Area)

The impact of the new RCOG 2019 curriculum and COVID-19 pandemic on Gynaecological training amongst the Specialist Registrars in the UK
E. Ovarian cancer
Velji
Barakat
United Kingdom
Poster session B +
ePoster
PB-079
29 Oct
08:00-18:00
Poster Area (Exhibition Area)

Selection of preexisting BRCA1/2-proficient tumor cells in BRCA1/2-mutated ovarian carcinomas treated by neoadjuvant chemotherapy
E. Ovarian cancer
Eriksson
Barakat
Sweden
Poster session B +
ePoster
PB-078
29 Oct
08:00-18:00
Poster Area (Exhibition Area)

Minimally invasive versus open pelvic exenteration in gynecological malignancies: a propensity-matched survival analysis
E. Ovarian cancer
Eriksson
Nicolò
Germany
Poster session B +
ePoster
PB-081
29 Oct
08:00-18:00
Poster Area (Exhibition Area)

E. Ovarian cancer
Berton
Lima
Italy
Poster session B +
ePoster
PB-077
29 Oct
08:00-18:00
Poster Area (Exhibition Area)

Sentinel-node biopsy in early-stage ovarian cancer: preliminary results of a prospective multicentre study
E. Ovarian cancer
Simpson
Monterrey Macias
France
Poster session B +
ePoster
PB-076
29 Oct
08:00-18:00
Poster Area (Exhibition Area)

Laparoscopic cytoreduction and complex debulking surgery in advanced low grade serous ovarian cancer: a secondary analysis of the OMA trial
E. Ovarian cancer
Kirsch
Velji
United Kingdom
Poster session B +
ePoster
PB-083
29 Oct
08:00-18:00
Poster Area (Exhibition Area)

The impact of the new RCOG 2019 curriculum and COVID-19 pandemic on Gynaecological training amongst the Specialist Registrars in the UK
E. Ovarian cancer
Velji
Barakat
United Kingdom
Poster session B +
ePoster
PB-079
29 Oct
08:00-18:00
Poster Area (Exhibition Area)

Selection of preexisting BRCA1/2-proficient tumor cells in BRCA1/2-mutated ovarian carcinomas treated by neoadjuvant chemotherapy
E. Ovarian cancer
Eriksson
Barakat
Sweden
Poster session B +
ePoster
PB-078
29 Oct
08:00-18:00
Poster Area (Exhibition Area)

Minimally invasive versus open pelvic exenteration in gynecological malignancies: a propensity-matched survival analysis
E. Ovarian cancer
Eriksson
Nicolò
Germany
Poster session B +
ePoster
PB-081
29 Oct
08:00-18:00
Poster Area (Exhibition Area)

E. Ovarian cancer
Berton
Lima
Italy
Poster session B +
ePoster
PB-077
29 Oct
08:00-18:00
Poster Area (Exhibition Area)

Sentinel-node biopsy in early-stage ovarian cancer: preliminary results of a prospective multicentre study
E. Ovarian cancer
Simpson
Monterrey Macias
France
Poster session B +
ePoster
PB-076
29 Oct
08:00-18:00
Poster Area (Exhibition Area)

Laparoscopic cytoreduction and complex debulking surgery in advanced low grade serous ovarian cancer: a secondary analysis of the OMA trial
E. Ovarian cancer
Kirsch
Velji
United Kingdom
Poster session B +
ePoster
PB-083
29 Oct
08:00-18:00
Poster Area (Exhibition Area)

The impact of the new RCOG 2019 curriculum and COVID-19 pandemic on Gynaecological training amongst the Specialist Registrars in the UK
E. Ovarian cancer
Velji
Barakat
United Kingdom
Poster session B +
ePoster
PB-079
29 Oct
08:00-18:00
Poster Area (Exhibition Area)

Selection of preexisting BRCA1/2-proficient tumor cells in BRCA1/2-mutated ovarian carcinomas treated by neoadjuvant chemotherapy
E. Ovarian cancer
Eriksson
Barakat
Sweden
Poster session B +
ePoster
PB-078
29 Oct
08:00-18:00
Poster Area (Exhibition Area)

Minimally invasive versus open pelvic exenteration in gynecological malignancies: a propensity-matched survival analysis
E. Ovarian cancer
Eriksson
Nicolò
Germany
Poster session B +
ePoster
PB-081
29 Oct
08:00-18:00
Poster Area (Exhibition Area)

E. Ovarian cancer
Berton
Lima
Italy
Poster session B +
ePoster
PB-077
29 Oct
08:00-18:00
Poster Area (Exhibition Area)

Sentinel-node biopsy in early-stage ovarian cancer: preliminary results of a prospective multicentre study
E. Ovarian cancer
Simpson
Monterrey Macias
France
Poster session B +
ePoster
PB-076
29 Oct
08:00-18:00
Poster Area (Exhibition Area)
<table>
<thead>
<tr>
<th>Title</th>
<th>Author(s)</th>
<th>Country</th>
<th>Session</th>
<th>Abstract Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Cervical cancer</td>
<td>Christina</td>
<td>United Kingdom</td>
<td>Poster session B</td>
<td>ePoster</td>
</tr>
<tr>
<td>6. Ovarian cancer</td>
<td>Wuems</td>
<td>United Kingdom</td>
<td>Poster session B</td>
<td>ePoster</td>
</tr>
<tr>
<td>2. Pathology</td>
<td>Georgi</td>
<td>Estonia</td>
<td>Poster session B</td>
<td>ePoster</td>
</tr>
<tr>
<td>9. Prevention of gynecologic cancer</td>
<td>Anna</td>
<td>Italy</td>
<td>Poster session B</td>
<td>ePoster</td>
</tr>
<tr>
<td>9. Prevention of gynecologic cancer</td>
<td>Serena</td>
<td>Spain</td>
<td>Poster session B</td>
<td>ePoster</td>
</tr>
<tr>
<td>9. Prevention of gynecologic cancer</td>
<td>Faiza</td>
<td>United Kingdom</td>
<td>Poster session B</td>
<td>ePoster</td>
</tr>
<tr>
<td>9. Prevention of gynecologic cancer</td>
<td>Lara</td>
<td>Netherlands</td>
<td>Poster session B</td>
<td>ePoster</td>
</tr>
<tr>
<td>9. Prevention of gynecologic cancer</td>
<td>Kia Yung</td>
<td>Hong Kong</td>
<td>Poster session B</td>
<td>ePoster</td>
</tr>
<tr>
<td>3. Endometrial cancer</td>
<td>Suneng</td>
<td>China</td>
<td>ePoster</td>
<td></td>
</tr>
<tr>
<td>1. Cervical cancer</td>
<td>Berta</td>
<td>Spain</td>
<td>ePoster</td>
<td></td>
</tr>
<tr>
<td>1. Cervical cancer</td>
<td>Kirsten</td>
<td>United States</td>
<td>ePoster</td>
<td></td>
</tr>
<tr>
<td>1. Cervical cancer</td>
<td>Kirsten</td>
<td>United States</td>
<td>ePoster</td>
<td></td>
</tr>
<tr>
<td>1. Cervical cancer</td>
<td>Kirsten</td>
<td>United States</td>
<td>ePoster</td>
<td></td>
</tr>
<tr>
<td>1. Cervical cancer</td>
<td>Almass</td>
<td>Indonesia</td>
<td>ePoster</td>
<td></td>
</tr>
<tr>
<td>1. Cervical cancer</td>
<td>Mariem</td>
<td>Tunisia</td>
<td>ePoster</td>
<td></td>
</tr>
<tr>
<td>1. Cervical cancer</td>
<td>Ji</td>
<td>United States</td>
<td>ePoster</td>
<td></td>
</tr>
<tr>
<td>1. Cervical cancer</td>
<td>Irene</td>
<td>Italy</td>
<td>ePoster</td>
<td></td>
</tr>
<tr>
<td>1. Cervical cancer</td>
<td>Ayse</td>
<td>Turkey</td>
<td>ePoster</td>
<td></td>
</tr>
<tr>
<td>1. Cervical cancer</td>
<td>Martina</td>
<td>Czech Republic</td>
<td>ePoster</td>
<td></td>
</tr>
</tbody>
</table>

**Therapeutic Strategy on Disease-Free and Overall Survival of Cervical Cancer:**

- **1. Cervical cancer:** Katia Mahiou, France
- **1. Cervical cancer:** Nicola Bizzari, Italy
- **1. Cervical cancer:** Emmanuel Kalagnokas, Greece

**Cervical Cancer in Tunisia: Multicentric Epidemiological Study:**

- **1. Cervical cancer:** Mariem Garcia, Tunisia
- **1. Cervical cancer:** Ri Sam, United States
- **1. Cervical cancer:** Irene Iavarone, Italy
- **1. Cervical cancer:** Ayse Filliz, Golmen Karasu, Turkey
- **1. Cervical cancer:** Martina Romanov, Czech Republic

**Deep Learning-Based Endometrial Segmentation and Automated Ultrasound Profiling from Histopathological Whole Slide Images:**

- **1. Cervical cancer**
- **6. Ovarian cancer**
- **1. Cervical cancer**
- **6. Ovarian cancer**
- **1. Cervical cancer**

**Use of Radiotherapy Planning CT Scans to Predict Risk of Insufficiency Fracture Following Pelvic Radiotherapy:**

- **10. Quality of life after treatment**
- **Amy Cooper**
- **United Kingdom**
- **Poster session B**
- **ePoster**
<table>
<thead>
<tr>
<th>ID</th>
<th>Title</th>
<th>Authors</th>
<th>Country</th>
<th>Type</th>
<th>Dates</th>
<th>Area</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>430</td>
<td>Prognostic value of systemic inflammatory markers in cervical cancer</td>
<td>1. Cervical cancer</td>
<td>Agne</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Vitkauskaitė</td>
<td>Lithuania</td>
<td>ePoster</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>443</td>
<td>Lymph node involvement in early-stage cervical cancer: is the</td>
<td>1. Cervical cancer</td>
<td>Matteo</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>lymphangiogenesis a risk factor? Results of MICROCOL study</td>
<td>Tantari</td>
<td>Switzerland</td>
<td>ePoster</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>582</td>
<td>Lymphoepithelioma-like carcinoma of the uterine cervix: A three-</td>
<td>1. Cervical cancer</td>
<td>Najla</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>case study</td>
<td>Attia</td>
<td>Tunisia</td>
<td>ePoster</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>594</td>
<td>Application of ultrasound in cervical cancer (a case report and</td>
<td>1. Cervical cancer</td>
<td>Dusan</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>updated literature review)</td>
<td>Djokovic</td>
<td>Portugal</td>
<td>ePoster</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>601</td>
<td>Fighting Cervical Cancer in Cameroon</td>
<td>1. Cervical cancer</td>
<td>Cristina</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Juan Jimenez</td>
<td>Spain</td>
<td>ePoster</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>611</td>
<td>THE PERSISTENCE OF VPH</td>
<td>1. Cervical cancer</td>
<td>Maria Dolores</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Rodriguez</td>
<td>Garcia</td>
<td>ePoster</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>619</td>
<td>Less is more? Simple hysterectomy versus radical hysterectomy in</td>
<td>1. Cervical cancer</td>
<td>Anastasios</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>FIGO 2018 stage IA2 cervical carcinoma: a Pan-Birmingham</td>
<td>Transaulis</td>
<td>United Kingdom</td>
<td>ePoster</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Gynaecological Cancer Centre population-based longitudinal cohort</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>620</td>
<td>Querrel's Morice type A hysterectomy for low-risk early-stage FIGO</td>
<td>1. Cervical cancer</td>
<td>Anastasios</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>2018 IA2-IB1 cervical cancer: a UK population-based retrospective</td>
<td>Transaulis</td>
<td>United Kingdom</td>
<td>ePoster</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>cohort study</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>655</td>
<td>INVOLVEMENT OF THE MARGINS AFTER EXCISIONAL TREATMENT</td>
<td>1. Cervical cancer</td>
<td>Maria Dolores</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Rodriguez</td>
<td>Garcia</td>
<td>ePoster</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>661</td>
<td>h-SIL IN YOUNG PATIENTS</td>
<td>1. Cervical cancer</td>
<td>Cordoba</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Abel</td>
<td>France</td>
<td>ePoster</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>681</td>
<td>Contribution of interstitial needles during image guided Brachytherapy</td>
<td>1. Cervical cancer</td>
<td>Vincent</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>BRCT8 after radiochemotherapy RCT in the management of locally</td>
<td>Cockenpot</td>
<td>France</td>
<td>ePoster</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>advanced cervical cancer LACC.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>after Radical Hysterectomy</td>
<td>Mendes</td>
<td>Portugal</td>
<td>ePoster</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>719</td>
<td>Impact of COVID-19 on radical (chemo)radiation for locally</td>
<td>1. Cervical cancer</td>
<td>Kathryn</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>advanced cervical cancer in the West of Scotland, April 2020- March</td>
<td>Graham</td>
<td>United Kingdom</td>
<td>ePoster</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>2021</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>721</td>
<td>Clinical outcomes of SBRT boost to the cervix as an alternative to</td>
<td>1. Cervical cancer</td>
<td>Kathryn</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>intracavitary brachytherapy in locally advanced cervical cancer</td>
<td>Graham</td>
<td>United Kingdom</td>
<td>ePoster</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Retrospective analysis from the West of Scotland</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>728</td>
<td>Strengthening of Pelvic Floor Muscles for Incontinence in Cervical</td>
<td>1. Cervical cancer</td>
<td>Prathepa</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Cancer</td>
<td>Jagdish</td>
<td>India</td>
<td>ePoster</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>773</td>
<td>Combined urethral and endovascular treatment of anterolateral</td>
<td>1. Cervical cancer</td>
<td>Joerg</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>fistula with fully covered stents</td>
<td>Nemyeyer</td>
<td>Germany</td>
<td>ePoster</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>791</td>
<td>Sentinel lymph node detection with Magtrace® in cervical cancer</td>
<td>1. Cervical cancer</td>
<td>Marcin</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Jedryka</td>
<td>Poland</td>
<td>ePoster</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>797</td>
<td>PET/CT negative predictive value in locally advanced cervical cancer</td>
<td>1. Cervical cancer</td>
<td>Myriam</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Gracia</td>
<td>Spain</td>
<td>ePoster</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>862</td>
<td>Simultaneous 18F-FDG PET/MRI as single imaging method in the</td>
<td>1. Cervical cancer</td>
<td>Karin</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>assessment of cervical cancer - a pilot study</td>
<td>Ståberg</td>
<td>Sweden</td>
<td>ePoster</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>958</td>
<td>Invasive stratified mucin producing intraepithelial lesion (EMILIE)</td>
<td>1. Cervical cancer</td>
<td>Zeinab</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>a rare entity of cervical cancer</td>
<td>Zemni</td>
<td>Tunisia</td>
<td>ePoster</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>971</td>
<td>LAPAROTOMY SPARED RATE IN TWO STEPS SURGERY FOR EARLY STAGE CERVICAL</td>
<td>1. Cervical cancer</td>
<td>Blanca</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>CANCER</td>
<td>Segarra Vidal</td>
<td>Spain</td>
<td>ePoster</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1002</td>
<td>Cervical carcinoma stage FIGO IA1 without lymphovascular space</td>
<td>1. Cervical cancer</td>
<td>Suzana</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>invasion: a 20 years conservative treatment in the South of Brazil</td>
<td>Pessini</td>
<td>Brazil</td>
<td>ePoster</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>University Hospital</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1005</td>
<td>INVASIVE CERVICAL CANCER OF ONE CERVIX IN UTERUS DILUTES TYPE OF</td>
<td>1. Cervical cancer</td>
<td>Miroslav</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>UTERINE ANOMALY - A CASE REPORT AND REVIEW OF THE LITERATURE</td>
<td>Popovici</td>
<td>Bosnia and Herzegovina</td>
<td>ePoster</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1034</td>
<td>Small Cell Neuroendocrine Carcinoma of the Cervix</td>
<td>1. Cervical cancer</td>
<td>Cosmin</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Sarac</td>
<td>Germany</td>
<td>ePoster</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1081</td>
<td>Effect of alpha-lipoic acid supplementation on regression of low-</td>
<td>1. Cervical cancer</td>
<td>Ivana</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>grade squamous intraepithelial lesions</td>
<td>Stošanović</td>
<td>Croatia</td>
<td>ePoster</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>with Chemoradiation</td>
<td>El-Medr</td>
<td>United Kingdom</td>
<td>ePoster</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1060</td>
<td>Retropertoneal paraotic lymph node staging in advanced cervical</td>
<td>1. Cervical cancer</td>
<td>Lamia</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>cancer: Tunisian Experience</td>
<td>Naja</td>
<td>Tunisia</td>
<td>ePoster</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1067</td>
<td>A laparoscopic radical hysterectomy safe in cervical cancer with</td>
<td>1. Cervical cancer</td>
<td>Junhean</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>tumor size ≤2 cm, even if parametral invasion or lymph node</td>
<td>Kim</td>
<td>Korea, Republic of</td>
<td>ePoster</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>metastasis is found after surgery?</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1070</td>
<td>Colposcopy Clinic Referens &amp; Cervical Cancer Diagnosis at a Veninary</td>
<td>1. Cervical cancer</td>
<td>Funmikola</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Gynaecology Centre Covering North &amp; East London during the COVID 19</td>
<td>Elsojø</td>
<td>United Kingdom</td>
<td>ePoster</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Pandemic</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1095</td>
<td>Conservative Management of CIN-2 A Retrophic, Single-Centre Study</td>
<td>1. Cervical cancer</td>
<td>Kattalin</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Lastak</td>
<td>United Kingdom</td>
<td>ePoster</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1107</td>
<td>Hysterectomy after Radical Vaginal Trachelectomy - is this a “must”</td>
<td>1. Cervical cancer</td>
<td>Irina</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>early stage cervical cancer? Our 15 years clinical experience</td>
<td>Capragna</td>
<td>Germany</td>
<td>ePoster</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>benchmarked with the current state of science</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1180</td>
<td>Nonfunctional complications associated with radical hysterectomy</td>
<td>1. Cervical cancer</td>
<td>Maria</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Alonso-Espías</td>
<td>Spain</td>
<td>ePoster</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Quality of life after extended pelvic exenterations

QUALITY OF LIFE FOLLOWING PELVIC EXTERATION FOR CERVICAL CANCER

Prevalence of Sexual dysfunction in patients with Gynecological Cancer

Pelvic exenteration with neurovacular and bony resections for gynecological tumors: a systematic review

Gynecological cancer treatment and couple’s sexuality

Hormone replacement therapy in gynecological cancer survivors and BRCA mutation carriers: a MITO group survey

Factors influencing short-term postoperative health-related quality of life deterioration in patients undergoing gynecologic oncologic critical care literature review

The follow-up of patients with high risk of ureteric postoperative complications - presentation of our prophylactic method.

Eliciate the mechanism of lymphedema from the analysis of lymphatic function and morphology before and after pelvic lymphadenectomies using indocyanine green fluorescence.

Cosmetic outcome and psychosexual distress after treatment for vulvar intraepithelial neoplasia

Does the use of long-term Aspirin reduce risk of post operative VTE in gynecological cancer patients?

Effect of elapsed time after treatment on overall quality of life, neurotoxicity, sexual life, lymphedema, and utility in ovarian cancer survivors (OVDOLS)

Frequency of bowel anastomosis leakage after modified posterior surgery

Cognitive function performance in gynecological cancer patients admitted to the high dependency unit postoperatively.

Cognitive function performance in patients undergoing maximal effort cytoreduction surgery for gynecological cancer management

Follow-up in Gynecological Cancer Survivors: an EORTC QLG-GCG Survivorship Study- Trial in Progress.

Digital health-related app support of patients with gynaecological cancers in aftercare - It’s like one part of the puzzle: Results from an explorative pilot study

Severe anaemia following frontline maintenance with PARP1 in a BRCA1 mutated high-grade serious ovarian cancer: an unexpected event

CERVICAL CANCER SURGERY AND MANAGEMENT OF INTRACTABLE PELVIC ABSCESES ON A BACKGROUND OF SEVERE CROHN’S DISEASE

Potentials and challenges of individualised aniontherapies for women with gynecological cancers in aftercare - It’s like one part of the puzzle: Results from an explorative study

Digital health-related app support of patients with gynecological malignancies: results of a pilot study

The quality of life of female refuges patients from Ukraine with gynecological cancers in aftercare - It’s like one part of the puzzle: Results from an explorative pilot study

Impact of Various Cervical Cancer Treatments on Sexual Functioning and Quality of Life of Women: a Systematic Review and Meta-Analysis

PROGNOSTIC ROLE OF TGF-β SIGNALLING PATHWAY ALTERATIONS IN ENDOMETRIAL CANCERS - A PROSPECTIVE CLINICAL STUDY

Preoperative circulating tumor DNA level is associated to poor overall survival in patients with ovarian cancer

Establishment of peritoneal DEC2 scaffolds for 3D culture of ovarian cancer organoids

TROP-2 expression and the tumor immune-microenvironment in cervical cancer

Functional Characterization of NRP2 in Endometrial Cancer: Mutations Associate with Aggressive Features while Low Expression Levels Predict Poor Survival

MLH1 promoter methylation analysis in patients with endometrial cancer stage I-II

SFRF-4OS-PECL/C1 in orthotopic mouse models of endometrial cancer: multiparametric characterization and evaluation of treatment response

STEK11 Adnexal Tumors: challenge of a new tumor entity
Use of vacuum-assisted closure after extensive flap dehiscence in vulvectomy for Paget's disease

13. Vaginal and vulvar cancer
Jitka Klikarová
Czech Republic ePoster
all Congress dates
Author locale: Exhibition Area

Patient-reported mobility and bicycle use after vulvar cancer surgery

13. Vaginal and vulvar cancer
Helena van Doorn
Netherlands ePoster
all Congress dates
Author locale: Exhibition Area

Minimally invasive inguinal lymph node dissection - Egyptian experience

13. Vaginal and vulvar cancer
Hisham Abdel Mageed
Egypt ePoster
all Congress dates
Author locale: Exhibition Area

Surgical management of early-stage melanoma of the female lower genital tract: a case series

13. Vaginal and vulvar cancer
Janine Zarragotia
Spain ePoster
all Congress dates
Author locale: Exhibition Area

Vulvar lymphangioma associated with squamous cell carcinoma

13. Vaginal and vulvar cancer
Zeineb Zemni
Tunisia ePoster
all Congress dates
Author locale: Exhibition Area

Can misdiagnosis be avoided in case of intestinal-type carcinoma of the vagina? A literature comprehensive review.

13. Vaginal and vulvar cancer
Stefania Perotto
Italy ePoster
all Congress dates
Author locale: Exhibition Area

Efficacy of hyperbaric oxygen therapy in vulvectomy healing

13. Vaginal and vulvar cancer
Zeineb Zemni
Tunisia ePoster
all Congress dates
Author locale: Exhibition Area

Management of early stage vulval cancer with groin sentinel lymph node sampling. A retrospective study in a cancer centre

13. Vaginal and vulvar cancer
Emmanouil Katsanevakis
United Kingdom ePoster
all Congress dates
Author locale: Exhibition Area

Vulvar basal cell carcinoma - 5 years experience from tertiary care centre and a case report of unusual recurrence of vulvar basal cell carcinoma in pagetic lymph nodes

13. Vaginal and vulvar cancer
Vid Jansa
Slovenia ePoster
all Congress dates
Author locale: Exhibition Area

Service evaluation of women with stage Ib vulval carcinoma who underwent groin sentinel lymph node biopsy: The South East Wales Oncological Oncology of the Centre of Oncology, Opole, Poland.

13. Vaginal and vulvar cancer
Hassan Zeinah
United Kingdom ePoster
all Congress dates
Author locale: Exhibition Area

Sarcevicious carcinoma (SC) of the vulva - A Case report and literature review

13. Vaginal and vulvar cancer
Hassan Zeinah
United Kingdom ePoster
all Congress dates
Author locale: Exhibition Area

Descriptive study of vulvar cancers according to the vulnerability of patients related to age: multicenter study

13. Vaginal and vulvar cancer
Emilie Raimond
France ePoster
all Congress dates
Author locale: Exhibition Area

Impact of age on surgical resection margins of vulvar squamous cell carcinoma: multicenter descriptive study

13. Vaginal and vulvar cancer
Emilie Raimond
France ePoster
all Congress dates
Author locale: Exhibition Area

Feasibility of Hand-Assisted Laparoscopic Sentinel Node Biopsy in Vulvar Cancer using Combined Radioactive and Fluorescence Guidance

13. Vaginal and vulvar cancer
Giuseppina Fais
Italy ePoster
all Congress dates
Author locale: Exhibition Area

Proactive management in vulvar radiotherapy facilitates treatment completion

13. Vaginal and vulvar cancer
Inbal Golomb
Israel ePoster
all Congress dates
Author locale: Exhibition Area

Metastatic Adenoid Cystic Carcinoma Gland Bartholin: A Case Report

13. Vaginal and vulvar cancer
vesna Irsic
Serbia ePoster
all Congress dates
Author locale: Exhibition Area

TOTAL VAGINALCTOMY FOR RECURRENT GYNECOLOGICAL CANCER: EXPERIENCE IN KAZSTOR.

13. Vaginal and vulvar cancer
Alima Safanova
Kazakhstan ePoster
all Congress dates
Author locale: Exhibition Area

Vulvar ectopic localization of breast cancer

13. Vaginal and vulvar cancer
Chemseddine Chekman
Algeria ePoster
all Congress dates
Author locale: Exhibition Area

Surgery after primary Chemoradiation in Locally Advanced Vulvar Cancer: Analysis of Surgical Outcomes and Survival

13. Vaginal and vulvar cancer
Giorgia Garganese
Italy ePoster
all Congress dates
Author locale: Exhibition Area

Multicenter experience on Sentinel Node Mapping in vulvar melanoma evaluation of clinical impact

13. Vaginal and vulvar cancer
Giorgia Garganese
Italy ePoster
all Congress dates
Author locale: Exhibition Area

Analysis of hospitalization of patients with malignant vulvar disease operated between 02.2020 and 04. 2022 in the Department of Oncological Gynecology of the Centre of Oncology, Opole, Poland.

13. Vaginal and vulvar cancer
Marcin Kalus
Poland ePoster
all Congress dates
Author locale: Exhibition Area

Introduction of care bundle in vulval cancer

13. Vaginal and vulvar cancer
Fatma AlWahaibi
United Kingdom ePoster
all Congress dates
Author locale: Exhibition Area

A comparison of methods to measure surface area of vulvar tumors

13. Vaginal and vulvar cancer
Helena van Doorn
Netherlands ePoster
all Congress dates
Author locale: Exhibition Area

Successful immunotherapy with imiquimod in vaginal intraepithelial lesion - a case report

13. Vaginal and vulvar cancer
Lucija Subiric
Croatia ePoster
all Congress dates
Author locale: Exhibition Area

Human papillomavirus-associated and -independent vulvar squamous cell carcinomas: clinical, pathological and prognostic distinct entities

13. Vaginal and vulvar cancer
Nuria Carreras-Dieguez
Spain ePoster
all Congress dates
Author locale: Exhibition Area

Vulvar primary melanoma: Report of Six cases and review of literature

13. Vaginal and vulvar cancer
Amani Jellali
Tunisia ePoster
all Congress dates
Author locale: Exhibition Area


13. Vaginal and vulvar cancer
Hassan Zeinah
United Kingdom ePoster
all Congress dates
Author locale: Exhibition Area

Small Cell Neuroendocrine Carcinoma of the Vagina

13. Vaginal and vulvar cancer
Ivais Puentes
Bogota ePoster
all Congress dates
Author locale: Exhibition Area

Topical imiquimod cream for recurrent vulvar Paget disease

13. Vaginal and vulvar cancer
Gennaro Cormio
Italy ePoster
all Congress dates
Author locale: Exhibition Area

Should immunotherapy be included as first-line adjuvant treatment in high-risk vulvar melanomas?

13. Vaginal and vulvar cancer
Virginia Benito
Spain ePoster
all Congress dates
Author locale: Exhibition Area

Prehabilitation to improve outcomes of patients with gynaecological cancer: a new window of opportunity

14. Organization of gynaecological cancer care Nathaniel Keidan
United Kingdom ePoster
all Congress dates
Author locale: Exhibition Area

Vaginal brachytherapy - the patient journey

14. Organization of gynaecological cancer care Tatiana Rabin
Israel ePoster
all Congress dates
Author locale: Exhibition Area
<table>
<thead>
<tr>
<th>ID</th>
<th>Title</th>
<th>Authors</th>
<th>Country</th>
<th>Type</th>
<th>Dates</th>
<th>Area</th>
</tr>
</thead>
<tbody>
<tr>
<td>876</td>
<td>Hysterectomy, pelvic or paraaortic lymphadenectomy: results of an outpatient pathway for surgery in gynecologic oncology</td>
<td>Adrien Boscher</td>
<td>France</td>
<td>ePoster</td>
<td>all Congress dates</td>
<td>(Exhibiton Area)</td>
</tr>
<tr>
<td>900</td>
<td>Wait time until surgery in gynecologic oncology: patient preference and experience</td>
<td>Kim van den Berg</td>
<td>Netherlands</td>
<td>ePoster</td>
<td>all Congress dates</td>
<td>(Exhibiton Area)</td>
</tr>
<tr>
<td>1154</td>
<td>Ovarian cancer management. Who cares for the Patient?A single case observational study</td>
<td>Jalid Sehouli</td>
<td>Germany</td>
<td>ePoster</td>
<td>all Congress dates</td>
<td>(Exhibiton Area)</td>
</tr>
<tr>
<td>1189</td>
<td>Challenges for a new robotic surgery program in gynecological oncology at a cancer center in the United Kingdom during COVID-19 pandemic</td>
<td>Ahmed AbdelBar</td>
<td>United Kingdom</td>
<td>ePoster</td>
<td>all Congress dates</td>
<td>(Exhibiton Area)</td>
</tr>
<tr>
<td>1197</td>
<td>Javazzo score®, an effort to preoperatively predict the duration of robotic assisted gynecological surgery</td>
<td>Christos Iavazzo</td>
<td>Greece</td>
<td>ePoster</td>
<td>all Congress dates</td>
<td>(Exhibiton Area)</td>
</tr>
<tr>
<td>1258</td>
<td>Patient Walk to the Operating Theatre as a New Tool for Patient Empowerment - KORE-INOVATION: The First Prospective Clinical Trial to assess a Perioperative Pathway to Reduce Postoperative Efficiencies</td>
<td>Marlene Lee</td>
<td>Germany</td>
<td>ePoster</td>
<td>all Congress dates</td>
<td>(Exhibiton Area)</td>
</tr>
<tr>
<td>1358</td>
<td>Cloud-Based Web Application to Reduce Delay in Cancer Treatment</td>
<td>Jack Le Bon</td>
<td>United Kingdom</td>
<td>ePoster</td>
<td>all Congress dates</td>
<td>(Exhibiton Area)</td>
</tr>
<tr>
<td>1366</td>
<td>Implementation of day case minimal access hysterectomy</td>
<td>Hannah Pierce</td>
<td>United Kingdom</td>
<td>ePoster</td>
<td>all Congress dates</td>
<td>(Exhibiton Area)</td>
</tr>
<tr>
<td>1395</td>
<td>Quality assessment as part of the quality assurance of a regional gynecological comprehensive cancer care network in the Netherlands</td>
<td>Cor de Kruon</td>
<td>Netherlands</td>
<td>ePoster</td>
<td>all Congress dates</td>
<td>(Exhibiton Area)</td>
</tr>
<tr>
<td>1443</td>
<td>Patient decision aids in genetic testing for women with ovarian cancer</td>
<td>Michal Sadurski</td>
<td>United Kingdom</td>
<td>ePoster</td>
<td>all Congress dates</td>
<td>(Exhibiton Area)</td>
</tr>
<tr>
<td>1574</td>
<td>Mirror conversations as part of the quality assurance of a regional gynecological comprehensive cancer care network in the Netherlands</td>
<td>Cor de Kruon</td>
<td>Netherlands</td>
<td>ePoster</td>
<td>all Congress dates</td>
<td>(Exhibiton Area)</td>
</tr>
<tr>
<td>1604</td>
<td>Efficiency of simulation program for OB/GYN residents using self-training and supervised sessions: a quantitative study</td>
<td>Katharina Aksoua</td>
<td>France</td>
<td>ePoster</td>
<td>all Congress dates</td>
<td>(Exhibiton Area)</td>
</tr>
<tr>
<td>1664</td>
<td>The need for a unified Approach in Patient Advocacy for Global Women’s Health: A PARSGO Initiative</td>
<td>Sara Nasser</td>
<td>Germany</td>
<td>ePoster</td>
<td>all Congress dates</td>
<td>(Exhibiton Area)</td>
</tr>
<tr>
<td>1658</td>
<td>Epidemic and war: lessons of cancer patients in Ukraine</td>
<td>Olina Postupalnenko</td>
<td>Ukraine</td>
<td>ePoster</td>
<td>all Congress dates</td>
<td>(Exhibiton Area)</td>
</tr>
<tr>
<td>1708</td>
<td>Will centralization of ovarian cancer treatment be beneficial in Poland ?</td>
<td>Jacek Szukowski</td>
<td>Poland</td>
<td>ePoster</td>
<td>all Congress dates</td>
<td>(Exhibiton Area)</td>
</tr>
<tr>
<td>267</td>
<td>Pelvic hydatidosis when is not an ovarian cancer in endemic region about 5 cases</td>
<td>Mariem Garci</td>
<td>Tunisia</td>
<td>ePoster</td>
<td>all Congress dates</td>
<td>(Exhibiton Area)</td>
</tr>
<tr>
<td>415</td>
<td>Sonography in the diagnosis of primary fallopian tube cancer</td>
<td>Natalia Roshkinova</td>
<td>Ukraine</td>
<td>ePoster</td>
<td>all Congress dates</td>
<td>(Exhibiton Area)</td>
</tr>
<tr>
<td>614</td>
<td>The role of ultrasound-guided biopsy in women with pelvic mass suspected of gynecological malignancy</td>
<td>Tufan Oğe</td>
<td>Turkey</td>
<td>ePoster</td>
<td>all Congress dates</td>
<td>(Exhibiton Area)</td>
</tr>
<tr>
<td>727</td>
<td>Performance of the IOTA ADNEX model in differentiating between benign and malignant adenocarcinomas in a Portuguese population</td>
<td>Dusan Djokovic</td>
<td>Portugal</td>
<td>ePoster</td>
<td>all Congress dates</td>
<td>(Exhibiton Area)</td>
</tr>
<tr>
<td>746</td>
<td>IMPLEMENTATION OF A COMPREHENSIVE CANCER GENOME PROFILING PROGRAMME INTO CLINICAL PRACTICE: AN ITALIAN EXPERIENCE IN A REFERRAL CENTRE FOR GYNECOLOGICAL CANCERS</td>
<td>Camilla Nero</td>
<td>Italy</td>
<td>ePoster</td>
<td>all Congress dates</td>
<td>(Exhibiton Area)</td>
</tr>
<tr>
<td>752</td>
<td>The efficacy of HPV test for cervical cancer screening</td>
<td>Hee young Song</td>
<td>Republic of Korea</td>
<td>ePoster</td>
<td>all Congress dates</td>
<td>(Exhibiton Area)</td>
</tr>
<tr>
<td>757</td>
<td>Biomechanical screening for cervical cancer</td>
<td>Ji Yun Hong</td>
<td>Republic of Korea</td>
<td>ePoster</td>
<td>all Congress dates</td>
<td>(Exhibiton Area)</td>
</tr>
<tr>
<td>776</td>
<td>Validity of whole body MRI in the preoperative assessment of ovarian cancer: systematic review and meta-analysis</td>
<td>Nabil Manzour</td>
<td>Spain</td>
<td>ePoster</td>
<td>all Congress dates</td>
<td>(Exhibiton Area)</td>
</tr>
<tr>
<td>779</td>
<td>How frequently benign uterine myomas appear as suspicious sarcomas on ultrasound examination</td>
<td>Nabil Manzour</td>
<td>Spain</td>
<td>ePoster</td>
<td>all Congress dates</td>
<td>(Exhibiton Area)</td>
</tr>
<tr>
<td>855</td>
<td>External validation of the ADNEX model to triage adnexal masses in Greece: A tertiary center study conducted by non-expert sonographers</td>
<td>Christos Anthoulakis</td>
<td>Greece</td>
<td>ePoster</td>
<td>all Congress dates</td>
<td>(Exhibiton Area)</td>
</tr>
<tr>
<td>900</td>
<td>Performance of a LAMP-based electrochemical biosensor for determination of high-risk HPV infection in clinical settings</td>
<td>Milan Anton</td>
<td>Czech Republic</td>
<td>ePoster</td>
<td>all Congress dates</td>
<td>(Exhibiton Area)</td>
</tr>
<tr>
<td>1115</td>
<td>Evaluation of cervical dysplasia with NOVaprep-mir-CERVIX</td>
<td>Olga Smirnova</td>
<td>Russian Federation</td>
<td>ePoster</td>
<td>all Congress dates</td>
<td>(Exhibiton Area)</td>
</tr>
<tr>
<td>1122</td>
<td>Dermoscopy for genital lesions</td>
<td>Iris Wohlmuth-Wasser</td>
<td>Austria</td>
<td>ePoster</td>
<td>all Congress dates</td>
<td>(Exhibiton Area)</td>
</tr>
<tr>
<td>1316</td>
<td>Do other high risk HPV types positive cases deserve colposcopy?</td>
<td>Seheran Iscan</td>
<td>Turkey</td>
<td>ePoster</td>
<td>all Congress dates</td>
<td>(Exhibiton Area)</td>
</tr>
<tr>
<td>1352</td>
<td>Dose received by axillary lymph nodes in breast cancer adjuvant radiation therapy</td>
<td>Najia Attia</td>
<td>Tunisia</td>
<td>ePoster</td>
<td>all Congress dates</td>
<td>(Exhibiton Area)</td>
</tr>
<tr>
<td>1408</td>
<td>INTRACARDIAC INTRAVENTOUS LEIOMYOMATOSIS WITH MALIGNTANT HISTOLOGICAL FEATURES</td>
<td>Dianelle Soto Troya</td>
<td>Colombia</td>
<td>ePoster</td>
<td>all Congress dates</td>
<td>(Exhibiton Area)</td>
</tr>
<tr>
<td>1563</td>
<td>Pre-Operative ultrasound assessment of rectosigmoid infiltration in advanced ovarian cancer</td>
<td>Silvia Gómez Carballo</td>
<td>Spain</td>
<td>ePoster</td>
<td>all Congress dates</td>
<td>(Exhibiton Area)</td>
</tr>
<tr>
<td>1650</td>
<td>Sonographic assessment of features suspicious of uterine sarcoma: evaluation of their use in preoperative prediction of malignancy</td>
<td>Hubertina Reina</td>
<td>Switzerland</td>
<td>ePoster</td>
<td>all Congress dates</td>
<td>(Exhibiton Area)</td>
</tr>
</tbody>
</table>
Ovarian cancer treatment planning and computer tomography interpretation skills of oncogynaecologist

Hydrocystic pelvic masses presenting with venous thromboembolism: what is the risk and is what the underlying pathology?

New ultrasonographic markers of borderline ovarian tumours (BOT)

Diagnostic accuracy of the IOTA ADNEX model for borderline ovarian tumors

How to differentiate between true positives and false positives in the diagnosis of borderline ovarian tumors

Inconclusive ovarian tumours by IOTA simple rules and application of O.RADS MRI scores in a tertiary referral centre.

Cydroectomy in recurrent endometrial cancer: a new paradigm for surgical management?

PROGNOSTIC SIGNIFICANCE OF MOLECULAR GENETIC FACTORS IN ENDOMETRIAL CANCER. A MODERN APPROACH TO THE PROBLEM.

Does order of adjuvant treatment for high risk endometrial cancer matter? A retrospective review.

Correlation between tumor distance from serosa and of myometrial invasion in endometrial cancer measured by transvaginal sonography

Impact of Obesity on Outcomes of Endometrial Cancer: a Cohort Study

Cost-effectiveness of molecular profiling for endometrial neoplasia: a single institution experience

Laparoscopic versus open hysterectomy in type I endometrial cancer, a tertiary referral center experience

Risk factors and patterns of recurrence in patients with low-risk endometrial cancer

The value of different frailty indices in predicting short-term post-operative outcomes

CLINICAL-MOLECULAR CORRELATIONS OF ENDOMETRIAL CANCER. RETROSPECTIVE STUDY

Improving endometrial cancer assessment by combining the new biomarker of GE10nic profiling with surgical Extra uterine disease assessment. An introduction to EUGENE

Implementation of the new surgical management in endometrial cancer in accordance to ESGO/ESTRO/European guidelines for the management of patients with endometrial carcinoma by trainees in their Clinical training

Factors affecting survival outcomes of patients with clear cell endometrial carcinoma

Real-World Treatment Patients and Outcomes in Recurrent or Advanced Endometrial Cancer Patients Initiating 1st-Line Systemic Therapy: A Retrospective Chart Review Study

Sentinel Node Biopsy for Endometrial Cancer by Retroperitoneal Transvaginal Natural Orifice Transluminal Endoscopic Surgery

Sentinel Lymph Node Biopsy in Endometrial Cancer

THE IMPACT OF DELAY FROM DIAGNOSIS TO SURGERY IN ENDOMETRIAL CANCER

Contrasting outcomes in two cases of fallopian tube (fistula) as artifacts of uterine manipulation use in minimally invasive surgery (MIS) for endometrial cancer: Does it matter? A retrospective cohort study

Robotic sentinel lymph node detection in endometrial cancer - A pilot series at Guy's and St Thomas' Hospital.

Role of follow-up of stage one endometrial carcinoma for detection of recurrence

Clinical relevance of circulating ESR1 mutations during endocrine therapy for advanced hormone-dependent endometrial carcinoma

Medically unfit women with early-stage endometrial cancer treated with the levonorgestrel intrauterine system

Sentinel lymph node detection with Magtrace® in endometrial cancer

Challenge to individualised surgical treatment for uterine cancer by intraoperative-prediction of lymph node metastasis using mRNA biomarker and clinical variables

1252

RECURRENT OCCURRENCE OF ENDOMETRIAL CARCINOMA: DIAGNOSIS IN ASYMPTOMATIC PHASE COMPARED WITH SYMPTOMATIC RECURRENT. DOES IT HAVE ANY IMPACT?

3. Endometrial cancer
Maria Dolores Rodriguez
García
Spain
ePoster
all Congress dates
Author Voids (Exhibition Area)

845

Laparoscopic sentinel lymph node mapping in endometrial cancer: a retrospective single center observational study

3. Endometrial cancer
Anastasia Bagiastia
Greece
ePoster
all Congress dates
Author Voids (Exhibition Area)

849

SURVIVAL DIFFERENCES AMONG SURGICAL APPROACH IN ENDOMETRIAL CANCER

3. Endometrial cancer
Maria Dolores Rodriguez
García
Spain
ePoster
all Congress dates
Author Voids (Exhibition Area)

850

Iron prehabilitation in endometrial cancer patients waiting for surgery: a feasibility pilot study

3. Endometrial cancer
Eleftherios Zachariou
Greece
ePoster
all Congress dates
Author Voids (Exhibition Area)

881

Introduction of a Sentinel Lymph Node Protocol for Endometrial Cancer at a Regional Cancer Center in UK

3. Endometrial cancer
Fatma AlWahabi
United Kingdom
ePoster
all Congress dates
Author Voids (Exhibition Area)

888

Role of preoperative determination of molecular classification on endometrial biopsy in preoperative allocation into a risk category in endometrial cancer

3. Endometrial cancer
Laura Cárdenas Puigzelga
Spain
ePoster
all Congress dates
Author Voids (Exhibition Area)

947

Bi allelic loss of MSH2 in endometrial carcinoma, a case report

3. Endometrial cancer
Aisling Redmond
Ireland
ePoster
all Congress dates
Author Voids (Exhibition Area)

955

Endometrial cancer: lymphovascular space invasion is a negative prognostic factor.

3. Endometrial cancer
Christina Gennigens
Belgium
ePoster
all Congress dates
Author Voids (Exhibition Area)

963

the impact of low-volume metastasis on disease-free survival of women with apparent early-stage endometrial cancer underwent sentinel node biopsy: a retrospective study

3. Endometrial cancer
Stefania Perotto
Italy
ePoster
all Congress dates
Author Voids (Exhibition Area)

987

Molecular characterization of endometrial cancer with low volume metastasis in the sentinel lymph node: a multicentric international study

3. Endometrial cancer
Gabriella Schiardi
United States
ePoster
all Congress dates
Author Voids (Exhibition Area)

988

Clinical over and under estimation in patients who underwent hysterectomy for glandular endometrial hyperplasia

3. Endometrial cancer
Fundu Altalay
Turkey
ePoster
all Congress dates
Author Voids (Exhibition Area)

992

Incidence and the clinical characteristics of endometrial cancer in end-bx performed with pipelle in breast cancer patients

3. Endometrial cancer
Fundu Altalay
Turkey
ePoster
all Congress dates
Author Voids (Exhibition Area)

997

Long recurrence of endometrial adenocarcinoma: impact of molecular profile and role of local therapies on prognosis

3. Endometrial cancer
Ana Izarraga
Spain
ePoster
all Congress dates
Author Voids (Exhibition Area)

1000

Review of adherence to NICE guidance on Lynch syndrome testing for patients diagnosed with endometrial cancer in BHTCT

3. Endometrial cancer
Charlotte Ralston
United Kingdom
ePoster
all Congress dates
Author Voids (Exhibition Area)

1004

The impact of cytoreductive surgery in FIGO IV and recurrent endometrial cancer

3. Endometrial cancer
Aleksandra Strojna
Germany
ePoster
all Congress dates
Author Voids (Exhibition Area)

1012

The role of inflammatory markers in the preoperative diagnosis of endometrial cancer and endometrial hyperplasia

3. Endometrial cancer
Cemal Altalay
Turkey
ePoster
all Congress dates
Author Voids (Exhibition Area)

1017

Concurrent endometrial carcinoma in hysterectomy specimens in patients with atypical endometrial hyperplasia

3. Endometrial cancer
Cemal Altalay
Turkey
ePoster
all Congress dates
Author Voids (Exhibition Area)

1019

Endometrial hyperplasia and cancer: results of two reference hospitals in Ankara

3. Endometrial cancer
Fundu Altalay
Turkey
ePoster
all Congress dates
Author Voids (Exhibition Area)

1047

Surgical restaging of early-stage endometrial cancer patients with lymphovascular invasion does not significantly impact their survival outcomes.

3. Endometrial cancer
Stamaties Petousis
France
ePoster
all Congress dates
Author Voids (Exhibition Area)

1053

Cases of bariatric surgery in Korean women with endometrial cancer: preliminary results

3. Endometrial cancer
Hyegeon Jo
Korea, Republic of
ePoster
all Congress dates
Author Voids (Exhibition Area)

1073

LOCAL EXPRESSION OF INSULIN LIKE GROWTH FACTOR 1 (IGF1)-RELATED COMPONENTS MIGHT INFLUENCE THE PROGNOSIS OF ENDOMETRIOSIS ENDOMETRIAL CARCINOMA (EC)

3. Endometrial cancer
Mohamad Nasir Shafiee
Malaysia
ePoster
all Congress dates
Author Voids (Exhibition Area)

1085

Using Data-Driven Algorithms and Real-World Data for Updating Endometrial Clinical Practice Guidelines

3. Endometrial cancer
Olga van der Hef
Netherlands
ePoster
all Congress dates
Author Voids (Exhibition Area)

1124

Predictors of invasive carcinoma in endometrial hyperplasia and its influence on surgical management

3. Endometrial cancer
María Alonso-Espías
Spain
ePoster
all Congress dates
Author Voids (Exhibition Area)

1128

Has endometrial cancer treatment changed during the last years? A cancer registry data-based approach to monitor expected treatment changes after the release of the corresponding S3 guideline.

3. Endometrial cancer
Anne-Marie Schultz
Germany
ePoster
all Congress dates
Author Voids (Exhibition Area)

1129

Anemia of cancer, transfusion rates and frailty status predict survival in women with endometrial cancer

3. Endometrial cancer
Katharina Aric
Germany
ePoster
all Congress dates
Author Voids (Exhibition Area)

1183

LMPYHEDEMA APPEARANCE ACCORDING TO NODAL STAGING IN ENDOMETRIAL CANCER

3. Endometrial cancer
Virginia García-Pineda
Spain
ePoster
all Congress dates
Author Voids (Exhibition Area)

1246

Risk factors for recurrence of endometrial cancer in Taiwanese women

3. Endometrial cancer
Chi-Chang Chang
Taiwan
ePoster
all Congress dates
Author Voids (Exhibition Area)

1252

Surgical management of Endometrial Carcinoma with a focus on the high BMI patient

3. Endometrial cancer
Aisling Redmond
Ireland
ePoster
all Congress dates
Author Voids (Exhibition Area)

1304

Molecular testing of endometrial carcinoma brings growing opportunity to identify patients with inherited risk of cancer

3. Endometrial cancer
Marketa Bednarikova
Czech Republic
ePoster
all Congress dates
Author Voids (Exhibition Area)

1314

Evaluation of the concentration of the soluble form of programmed cell death ligand 2 in patients with endometrial cancer.

3. Endometrial cancer
Weronika Kurylko
Poland
ePoster
all Congress dates
Author Voids (Exhibition Area)

1315

Anti-LSR monoclonal antibody exerts an antitumor activity associated with apoptosis in endometrial cancer

3. Endometrial cancer
Yoshikazu Nagase
Japan
ePoster
all Congress dates
Author Voids (Exhibition Area)

1322

A feasibility study of endometrial cavity cytological sampling for precision treatment in endometrial cancer

3. Endometrial cancer
Monika Sobocan
Slovenia
ePoster
all Congress dates
Author Voids (Exhibition Area)

1323

Endometrial cancer aggressiveness may be associated with exposure to phthalates

3. Endometrial cancer
June Knez
Slovenia
ePoster
all Congress dates
Author Voids (Exhibition Area)
1631 ABC of Surgical Teaching: Time to Consider a Global Blueprint for Holistic Education
5. Miscellaneous Elif Iliya Emin United Kingdom ePoster all Congress dates ePoster (Exhibition Area)

1632 Breast carcinosarcoma: a report of an extremely rare entity with a review of the literature
5. Miscellaneous Amani Jellaï Tunisia ePoster all Congress dates ePoster (Exhibition Area)

1639 Management of primary & secondary breast lymphoma
5. Miscellaneous Amani Jellaï Tunisia all Congress dates ePoster (Exhibition Area)

1673 The Digital Trans-African e-Health Network: A clinical Partnership Experience
5. Miscellaneous Sara Nassier Germany all Congress dates ePoster (Exhibition Area)

1684 Primary Neuroendocrine Tumors of The Breast: A Series of Five Cases
5. Miscellaneous Amani Jellaï Tunisia all Congress dates ePoster (Exhibition Area)

1686 Pure Ductal Carcinoma in Situ in The Male Breast: An Uncommon Entity
5. Miscellaneous Amani Jellaï Tunisia all Congress dates ePoster (Exhibition Area)

1691 A RARE CASE OF THE TALL CELL CARCINOMA OF THE BREAST WITH REVERSED POLARITY
5. Miscellaneous Amani Jellaï Tunisia all Congress dates ePoster (Exhibition Area)

1698 Benign metastasizing leiomyoma diagnosed in postmenopausal patients with suspected malignant ovarian peritoneal carcinoma: report of two cases and review of literature
5. Miscellaneous Osmar Rangel Neto Brazil all Congress dates ePoster (Exhibition Area)

173 Endometrioid Borderline Ovarian Tumor: Clinical Characteristics, Prognosis and Management
6. Ovarian cancer Giulio Ricotta Italy ePoster all Congress dates ePoster (Exhibition Area)

198 A validation study of two pre-operative predictive models in the treatment planning of advanced ovarian cancer
6. Ovarian cancer Amy Shearer United Kingdom ePoster all Congress dates ePoster (Exhibition Area)

216 Identification and Characterization ofCA-125, IL-2, IL-13 and H4 in Vaginal Fluid in Ovarian Cancer
6. Ovarian cancer Arl Reiss Israel ePoster all Congress dates ePoster (Exhibition Area)

244 Prognostic Value of Peritoneal Cancer Index after Complete Cytoreductive surgery in Advanced Ovarian Cancer
6. Ovarian cancer Milhæl Asp Sweden ePoster all Congress dates ePoster (Exhibition Area)

245 Ovarian tumor frozen section, a multidisciplinary affair
6. Ovarian cancer Milhæl Asp Sweden ePoster all Congress dates ePoster (Exhibition Area)

272 “Double O” technique of bowel anastomosis
6. Ovarian cancer Olyslagee Ts United Kingdom ePoster all Congress dates ePoster (Exhibition Area)

275 Comparison of patients with trucal biopsy, acid cytology with final pathology results from patients operated with prediagnosis of ovarian cancer
6. Ovarian cancer Fatma Basak Tanoglu Turkey ePoster all Congress dates ePoster (Exhibition Area)

367 Rucaparib in Clinical Practice - What are the elements of patient adherence?
6. Ovarian cancer Elena-Ioana Braicu Germany ePoster all Congress dates ePoster (Exhibition Area)

369 Cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy in patients with advanced ovarian cancer: 2years survival analysis
6. Ovarian cancer Farah Farzaneh Iran, Islamic Republic of ePoster all Congress dates ePoster (Exhibition Area)

374 Primary ovarian non-Hodgkin’s lymphoma: a case report
6. Ovarian cancer Iaya Shirezadeh Iran, Islamic Republic of ePoster all Congress dates ePoster (Exhibition Area)

402 Proteomic analysis of exosomes secreted during mesenchymal-epithelial transition for potential diagnosis of mesenchymal subtype of high grade ovarian serous carcinoma
6. Ovarian cancer Francisco Candido dos Reis Brazil ePoster all Congress dates ePoster (Exhibition Area)

420 Treatment and outcome of patients with high-grade advanced ovarian cancer (ADC) - Real world data of the German Quality Assurance Project (OS Chir of the AGO Study Group)
6. Ovarian cancer Sven Mahner Germany ePoster all Congress dates ePoster (Exhibition Area)

429 CLINICAL CYTOLOGY AND CELL BLOCK IN THE DIAGNOSIS OF ADVANCED OVARIAN CANCER
6. Ovarian cancer Swarna Banerjee India ePoster all Congress dates ePoster (Exhibition Area)

431 Clinicopathologic features and outcomes of mucinous ovarian tumours: a retrospective study
6. Ovarian cancer Emmanouil Katsanosvaki United Kingdom ePoster all Congress dates ePoster (Exhibition Area)

435 Significance of the peritoneal washing cytology as a predictive factor of the long-term benefit of secondary debulking surgery for ovarian cancer
6. Ovarian cancer Hiroaki Nagano Japan ePoster all Congress dates ePoster (Exhibition Area)

437 Meta-Analyses Reveal Serum or Plasma Interleukin-6 As a Biomarker for Malignant Ovarian Neoplasia.
6. Ovarian cancer Andrei Pasca Romania ePoster all Congress dates ePoster (Exhibition Area)

439 UP-NEXT (ENGOT-ov31-RG6-GO349): A Study of Four Upfront Platinum-Based Regimens in Advanced Ovarian Cancer
6. Ovarian cancer Mansoor Mieza Denmark ePoster all Congress dates ePoster (Exhibition Area)

448 Venous thromboembolic disease in ovarian cancer: incidence, impact on overall survival and development of a predictive score
6. Ovarian cancer Anne-Sophie Bats France ePoster all Congress dates ePoster (Exhibition Area)

456 Gyna-E-Oncology Surgeons’ readiness to undertake colo-rectal procedures during cytoreductive surgery for ovarian cancer: a cross-sectional survey
6. Ovarian cancer Daniel Huddart United Kingdom ePoster all Congress dates ePoster (Exhibition Area)

459 UPUF-T (ENGOT-ov6-GO340): A Registrational Trial of Upfront Platinum-Based Rilrostonide (uprist) or NabP1b-directed Antibody Drug Conjugate (ADC) in Platinum-sensitive Recurrent Ovarian Cancer
6. Ovarian cancer Nicole Concin Germany ePoster all Congress dates ePoster (Exhibition Area)

576 Expression VIII - First study of individual perception and level of information of patients with low grade ovarian cancer and borderline tumor of the ovary in 323 patients
6. Ovarian cancer Laura Beckmann Germany ePoster all Congress dates ePoster (Exhibition Area)

588 Telematic colonoscopy monotherapy and in combination with pembrolizumab in patients with advanced solid tumours: ARTISTRY
6. Ovarian cancer Jessica Rege United States ePoster all Congress dates ePoster (Exhibition Area)

593 Primary Ovarian Non-Hodgkin Lymphoma: Report of Three Cases and the Role of International Online Meetings in Clinical Decision Making
6. Ovarian cancer Basil Reffay Egypt ePoster all Congress dates ePoster (Exhibition Area)

599 A Real World Perspective of PARP inhibitors maintenance therapy in relapsed platinum-sensitive ovarian cancer patients
6. Ovarian cancer Menno Fouda United Kingdom ePoster all Congress dates ePoster (Exhibition Area)

602 Prognostic factors for recurrence in adult-type granulosa cell tumours of the ovary and survival outcomes after secondary and tertiary cytoreductive surgery: a UK population-based cohort study
6. Ovarian cancer Anastasios Tranoulis United Kingdom ePoster all Congress dates ePoster (Exhibition Area)
603 The Effect of Oral Metronomic Chemotherapy on Recurrent Progressive Ovarian Cancer.
E. Ovarian cancer
Swarna banerjee
India
ePoster
all Congress dates
Author(s) India

606 Management of borderline ovarian tumors: A tertiary referral center experience in Egypt
E. Ovarian cancer
Khaled Gaballa
Egypt
ePoster
all Congress dates
Author(s) Egypt

617 The role of somatic and para-aneurysmal lymphadenectomy in the management of advanced epithelial ovarian, tubal, and peritoneal cancer: a systematic review and meta-analysis.
E. Ovarian cancer
Alexander Tzanis
Greece
ePoster
all Congress dates
Author(s) Greece

618 Apoptosis maintenance therapy after first-line chemotherapy: A real-world assessment of patients with ovarian cancer who received pazopanib first-line maintenance therapy in the United States
E. Ovarian cancer
Ritu Safani
United States
ePoster
all Congress dates
Author(s) United States

630 The expression of POLE-DNA polymerase A is a predictive biomarker for platinum resistance and poor prognosis in epithelial ovarian cancer by regulating cell cycle
E. Ovarian cancer
Gwan Hye Han
Korea, Republic of
Korea
ePoster
all Congress dates
Author(s) Korea, Republic of Korea

634 Current management of peritoneal carcinomatosis in patients who experienced disease progression after PARR maintenance: a real-life data control study
E. Ovarian cancer
Laura Vertechy
Italy
ePoster
all Congress dates
Author(s) Italy

636 Does heart-rate variability predict prognosis in women with ovarian cancer?
E. Ovarian cancer
Mirit Todolano-Hacohen
Israel
ePoster
all Congress dates
Author(s) Israel

637 Five-Year Universal Tumor Screening of BRCA1/2 in Epithelial Ovarian Carcinoma: a History-Directed HR-Deficiency Testing Initiative
E. Ovarian cancer
Claire Kramer
Netherlands
ePoster
all Congress dates
Author(s) Netherlands

643 MUCINOUS OVARIAN CANCERS - A SINGLE INSTITUTION ANALYSIS OF CLINICOPATHOLOGIC PROFILE AND SURVIVAL OUTCOMES
E. Ovarian cancer
Deepak Bose
India
ePoster
all Congress dates
Author(s) India

644 Survival impact of histological response to neoadjuvant chemotherapy according to number of cycles in patients with advanced ovarian cancer
E. Ovarian cancer
Alejandra Martinez
France
ePoster
all Congress dates
Author(s) France

645 Contraceptives and cancer risks in BRCA1/2 pathogenic variant carriers: a systematic review and meta-analysis
E. Ovarian cancer
Majke van Bommel
Netherlands
ePoster
all Congress dates
Author(s) Netherlands

647 Real-world therapy and clinical and patient-reported outcomes in patients with newly diagnosed advanced ovarian cancer: First Description of the SCOUT-1 study centers (NOGGO vs54)
E. Ovarian cancer
Sehouri
Germany
ePoster
all Congress dates
Author(s) Germany

649 Response to treatment and prognostic significance of supradiaphragmatic disease in patients with high-grade serous ovarian cancer
E. Ovarian cancer
Valentina Chiappa
Italy
ePoster
all Congress dates
Author(s) Italy

657 ENGOT-ovis/KEYNOTE-896: Phase 3, randomized, double-blind study of pembrolizumab versus placebo plus paclitaxel with optional bevacizumab for platinum-resistant recurrent ovarian cancer
E. Ovarian cancer
Nicoleta Colomba
Italy
ePoster
all Congress dates
Author(s) Italy

672 Comparison of quality of life in patients with platinum-sensitive recurrent ovarian, fallopian tube and peritoneal cancer treated with trabectedin plus pegylated liposomal doxorubicin (PLD) or standard platinum-based chemotherapy in first and second-line treatment settings
E. Ovarian cancer
Radoslav Chekerov
Germany
ePoster
all Congress dates
Author(s) Germany

673 Nanoparticle encapsulation improves periparotid parameters in women with advanced ovarian cancer subjected to cytoreductive surgery
E. Ovarian cancer
Kimon Chatzistamatiou
Greece
ePoster
all Congress dates
Author(s) Greece

676 Safety and Efficacy of NORMA-203 in Patients With Platinum-Resistant Ovarian Cancer: Results From the Expansion Part of a Phase 1 Trial in Japan
E. Ovarian cancer
Takuma Miura
Japan
ePoster
all Congress dates
Author(s) Japan

685 WHAT IS BEYOND BRCA MUTATIONAL STATUS IN HIGH GRADE SEROUS OVARIAN CANCER? THE ROLE OF HORMONE RECEPTORS EXPRESSION
E. Ovarian cancer
Emanuelle Perrone
Italy
ePoster
all Congress dates
Author(s) Italy

686 Paradigm Shift in Surgical Approach in the Management of Advanced Ovarian Cancer in the University Hospitals of Seccafiori
E. Ovarian cancer
Anas Barakat
United Kingdom
ePoster
all Congress dates
Author(s) United Kingdom

687 ARTISTRY: phase 3, multicenter study of nemvaleukin alfa plus pembrolizumab versus chemotherapy in patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer
E. Ovarian cancer
Jalid Sehouri
Germany
ePoster
all Congress dates
Author(s) Germany

688 Survival outcomes of advanced ovarian cancer patients undergoing maximal effort cytoreduction
E. Ovarian cancer
Eleftherios Zachariou
Greece
ePoster
all Congress dates
Author(s) Greece

704 Treatment patterns and time to next treatment among patients with OC in a real-life setting in Finland: the OORWE-Finland study
E. Ovarian cancer
Ouli Isomeri
Finland
ePoster
all Congress dates
Author(s) Finland

706 Prognostic impact of vagus nerve activity at initial management of ovarian cancer
E. Ovarian cancer
Florence Jolly
France
ePoster
all Congress dates
Author(s) France

708 Real-world assessment of patients with ovarian cancer who received niraparib as second-line maintenance therapy in the United States: did first-line maintenance approval change the patient profile for platinum-resistant recurrent ovarian cancer
E. Ovarian cancer
Floor Backes
United States
ePoster
all Congress dates
Author(s) United States

714 Full-thickness partial diaphragm resection using an Endo GIA stapler and low open standard techniques with macrocoating improves periparotid parameters in women with advanced ovarian cancer subjected to cytoreductive surgery
E. Ovarian cancer
Daniela Huber
Switzerland
ePoster
all Congress dates
Author(s) Switzerland

715 High expression of Vascular-ATPase subunit ATP6V1B1 predicts a poor prognosis and correlates with cell cycle progression in epithelial ovarian cancer
E. Ovarian cancer
Gwan Hye Han
Korea, Republic of
ePoster
all Congress dates
Author(s) Korea, Republic of Korea

718 Pretreatment 18F-FDG PET/CT metabolic parameters as predictors of non-complete cytoreduction in patients with epithelial ovarian cancer
E. Ovarian cancer
Felis Borja
Spain
ePoster
all Congress dates
Author(s) Spain

750 Improved staging of stage II ovarian tumors by 3D US
E. Ovarian cancer
Bielje Tans
Belgium
ePoster
all Congress dates
Author(s) Belgium

760 Advanced ovarian cancer imitating deep infiltrating endometriosis: Radical resection and reconstructive surgery of the anterior abdominal wall
E. Ovarian cancer
Piotr Lejka
Poland
ePoster
all Congress dates
Author(s) Poland

765 THE IMPACT OF DELAY FROM DIAGNOSIS TO SURGERY IN EARLY OVARIAN CANCER
E. Ovarian cancer
Dimitrios Zouzoulas
Greece
ePoster
all Congress dates
Author(s) Greece

771 MALIGNANT OVARIAN PENDIX ORIGINATED FROM BOTH OF OVARYS AND APPENDIX WITH SUBCUTANEOUS DEPLOYMENT IN UMBILICAL AND INSUFFLATION OF AN 68 YEARS OLD WOMAN CASE
E. Ovarian cancer
Glenn Budi Tanoyo
Indonesia
ePoster
all Congress dates
Author(s) Indonesia

785 Radical Surgical Procedures in Advanced Ovarian Cancer and Differences Between Primary and Interval Debunking Surgery
E. Ovarian cancer
George Kouklidis
United Kingdom
ePoster
all Congress dates
Author(s) United Kingdom

791 PRIMARY DEBULCKING SURGERY VERSUS NEOADJUVANT CHEMOTHERAPY AND INTERVAL DEBULCKING SURGERY FOR ADVANCED EPITHELIAL OVARIAN CANCER
E. Ovarian cancer
Lorena Gonzalez Gia
Spain
ePoster
all Congress dates
Author(s) Spain

796 Preoperative Neutrophil lymphocyte Ratio in ascites as a prognostic factor in epithelial ovarian cancer
E. Ovarian cancer
Yong Soek
Lee
Korea, Republic of
ePoster
all Congress dates
Author(s) Korea, Republic of Korea
798 Diagnosis of first relapse and its impact on quality of life in patients with advanced ovarian cancer (AGO-OVAR 19/11)
ePoster
E. Ovarian cancer
Phillip Harter
Germany
EPoster
all Congress dates
Poster kiosk (Exhibition Area)
812 SERUM MARKERS AND CYTOGENES IN PATIENTS WITH OVARIAN CANCER, BORDERLINE OR BENIGN OVARIAN TUMORS
ePoster
E. Ovarian cancer
Marek Nowak
Poland
EPoster
all Congress dates
Poster kiosk (Exhibition Area)
821 Dr., PhD student
ePoster
E. Ovarian cancer
Nikoline Karllsen
Denmark
EPoster
all Congress dates
Poster kiosk (Exhibition Area)
837 Characterization of long-term survivor and maintenance therapy in relapsed ovarian cancer (CAROLIN)-Intergroup study NOGGO / J-A-AGO
ePoster
E. Ovarian cancer
Jalidi Sehouli
Germany
EPoster
all Congress dates
Poster kiosk (Exhibition Area)
861 Transcriptome and genetic profile of epithelial ovarian carcinoma patients sensitive and resistant to platinum derivatives
ePoster
E. Ovarian cancer
Martin Hruda
Czech Republic
EPoster
all Congress dates
Poster kiosk (Exhibition Area)
865 Oncologic and fertility outcomes in advanced stage immature teratomas
ePoster
E. Ovarian cancer
Giuseppe Marino
Italy
EPoster
all Congress dates
Poster kiosk (Exhibition Area)
882 SURGICAL OUTCOME AFTER UPPER ABDOMINAL SURGERY PROCEDURES FOR OVARIAN CANCER
ePoster
E. Ovarian cancer
Evelina Karlsson
Sweden
EPoster
all Congress dates
Poster kiosk (Exhibition Area)
883 Rare Cancers in Gynecologic Oncology, ENGOT initiative for a European Registry
ePoster
E. Ovarian cancer
Alice Bergamini
Italy
EPoster
all Congress dates
Poster kiosk (Exhibition Area)
893 0 Ethnicity a Risk Factor for Differential Outcomes in Mucinous Ovarian Cancers? Experience from a UK Gynaecological Oncology Centre
ePoster
E. Ovarian cancer
Tejumola Olajoye
United Kingdom
EPoster
all Congress dates
Poster kiosk (Exhibition Area)
901 Open abdominal vacuum pack technique for the management of severe abdominal complications after cytoreductive surgery in ovarian cancer
ePoster
E. Ovarian cancer
Gwenaëll Ferron
France
EPoster
all Congress dates
Poster kiosk (Exhibition Area)
919 A pilot study of interval cytoreductive surgery and HIPEC for advanced epithelial ovarian cancer in the UK
ePoster
E. Ovarian cancer
Katja Aj
United Kingdom
EPoster
all Congress dates
Poster kiosk (Exhibition Area)
921 Systematic nurse-led consultations based on electronic patient-reported outcomes among women with gynaecological cancer during chemotherapy. The CONNECT study
ePoster
E. Ovarian cancer
Mille Christiansen
Denmark
EPoster
all Congress dates
Poster kiosk (Exhibition Area)
924 Distribution of BRCA1/2 mutations and clinical outcomes in epithelial ovarian, peritoneal, fallopian tube cancer: based on multicenter real-world data
ePoster
E. Ovarian cancer
Bihan Hong
Korea, Republic of
EPoster
all Congress dates
Poster kiosk (Exhibition Area)
939 Influence of cancer and surgery to immunosuppressive and proinflammatory factors in ovarian cancer patients' PBMCs
ePoster
E. Ovarian cancer
Arturas Sukovas
Lithuania
EPoster
all Congress dates
Poster kiosk (Exhibition Area)
941 LEBLC, a single-arm phase II trial to evaluate the safety of cediranib in the prevention of bowel perforation in platinum resistant ovarian cancer
ePoster
E. Ovarian cancer
Alexander Murphy
United Kingdom
EPoster
all Congress dates
Poster kiosk (Exhibition Area)
948 Deconvoluting Chemotherapy (FARCT) and Interval Debunking Surgery (IDS) in a Group of Patients with Advanced Stage Epithelial Ovarian Cancer, Unsuitable for Upfront Surgery
ePoster
E. Ovarian cancer
Ayesha Siddiqua
Bangladesh
EPoster
all Congress dates
Poster kiosk (Exhibition Area)
949 GOGOC: (Pros of Ovarian Cancer patients:how maintenance therapy affects their Lives) study: Patient preference for treatment formulation and administration
ePoster
E. Ovarian cancer
Dana Chase
United States
EPoster
all Congress dates
Poster kiosk (Exhibition Area)
950 Low grade and high grade serous ovarian cancer: comparison of surgical outcome after secondary cytoreductive surgery
ePoster
E. Ovarian cancer
Serena Cappuccio
Italy
EPoster
all Congress dates
Poster kiosk (Exhibition Area)
951 COMPARISON OF COMPLICATIONS IN PATIENTS UNDERGOING UPPER VERSUS LOWER ABDOMINAL CYTOREDUCTIVE SURGERY IN OVARIAN CANCER
ePoster
E. Ovarian cancer
Fatma Basak Tanoglu
Turkey
EPoster
all Congress dates
Poster kiosk (Exhibition Area)
961 Real-world prospective characterization of homologous recombination deficiency in advanced ovarian cancer
ePoster
E. Ovarian cancer
Matilda Salko
Finland
EPoster
all Congress dates
Poster kiosk (Exhibition Area)
965 Prevalence of Low Anterior Resection Syndrome in patients with advanced stage epithelial ovarian cancer
ePoster
E. Ovarian cancer
Mignon van Gent
Netherlands
EPoster
all Congress dates
Poster kiosk (Exhibition Area)
966 Tolerance of intraperitoneal (IP) ramucirumab after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in patients (pts) with relapsed advanced ovarian carcinoma- a single center retrospective study
ePoster
E. Ovarian cancer
Naoaul Bakrin
France
EPoster
all Congress dates
Poster kiosk (Exhibition Area)
970 There is no benefit for preoperative hyperhydration before cytoreductive surgery and HIPEC with cisplatin when combined with bevacizumab
ePoster
E. Ovarian cancer
Naoaul Bakrin
France
EPoster
all Congress dates
Poster kiosk (Exhibition Area)
980 Auranofin as a potential anticancer drug in epithelial ovarian cancer
ePoster
E. Ovarian cancer
Flavia Sorbi
Italy
EPoster
all Congress dates
Poster kiosk (Exhibition Area)
985 Predictors of recurrence in adult granulosa cell type ovarian cancer: a retrospective cohort study
ePoster
E. Ovarian cancer
Daniel Huddart
United Kingdom
EPoster
all Congress dates
Poster kiosk (Exhibition Area)
1010 Cystic malignant teratoma in a 33-year-old woman: a case report
ePoster
E. Ovarian cancer
vesna Krišć
Serbia
EPoster
all Congress dates
Poster kiosk (Exhibition Area)
1022 Implementation of machine learning in a care pathway for advanced epithelial ovarian cancer: a National Cancer Institute experience
ePoster
E. Ovarian cancer
Adrien Boucher
France
EPoster
all Congress dates
Poster kiosk (Exhibition Area)
1029 COMPARISON OF O-RADS AND IOTA ADNEX MODEL CRITERIA WITH PATHOLOGY RESULTS IN ADNEXIAL MASSES
ePoster
Ovarian cancer
Cemal Recat Atalay
Turkey
EPoster
all Congress dates
Poster kiosk (Exhibition Area)
1058 DEVELOPING INFRASTRUCTURE FOR MOLECULAR PROFILING FOR ALL IN OVARIAN CANCER (DEMO)
ePoster
E. Ovarian cancer
Elaine Leung
United Kingdom
EPoster
all Congress dates
Poster kiosk (Exhibition Area)
1063 There is no benefit for preoperative hyperhydration before cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) with cisplatin when combined with sodium thiosulfate
ePoster
E. Ovarian cancer
Elea Vachez
France
EPoster
all Congress dates
Poster kiosk (Exhibition Area)
1064 There is no benefit for preoperative hyperhydration before cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) with cisplatin when combined with sodium thiosulfate
ePoster
E. Ovarian cancer
Amaniel Keffeyuse
France
EPoster
all Congress dates
Poster kiosk (Exhibition Area)
1066 Metabolomics showed LSR promoted lipid metabolism in EOC
ePoster
E. Ovarian cancer
Hittomi Sakaguchi
Japan
EPoster
all Congress dates
Poster kiosk (Exhibition Area)
1068 Canadian practice patterns of primary treatment in advanced (stage II-IIIV) low grade serous ovarian carcinoma
ePoster
E. Ovarian cancer
Jordan Lewis
Canada
EPoster
all Congress dates
Poster kiosk (Exhibition Area)
<table>
<thead>
<tr>
<th>ID</th>
<th>Title</th>
<th>Authors</th>
<th>Country</th>
<th>Type</th>
<th>Dates</th>
<th>Venue</th>
<th>EPoster</th>
</tr>
</thead>
<tbody>
<tr>
<td>1072</td>
<td>Optimal Cytoreduction For Advanced Epithelial Ovarian Cancer: non invasive predictive factors</td>
<td>E. Ovarian cancer Giorgio Cardotti Italy</td>
<td>all Congress dates</td>
<td>EPoster</td>
<td>all Congress dates</td>
<td>EPoster</td>
<td>EPoster</td>
</tr>
<tr>
<td>1092</td>
<td>Identification and validation of microRNAs as endogenous controls in epithelial ovarian cancer</td>
<td>E. Ovarian cancer Joanna Lopacińska-Jaergensen Denmark</td>
<td>all Congress dates</td>
<td>EPoster</td>
<td>all Congress dates</td>
<td>EPoster</td>
<td>EPoster</td>
</tr>
<tr>
<td>1100</td>
<td>a retrospective analysis of prognostic radiological features in patients supported with parental nutrition</td>
<td>E. Ovarian cancer Rebecca Wight United Kingdom</td>
<td>all Congress dates</td>
<td>EPoster</td>
<td>all Congress dates</td>
<td>EPoster</td>
<td>EPoster</td>
</tr>
<tr>
<td>1103</td>
<td>Poly ADP-Ribose polymerase inhibitors as maintenance therapy for ovarian cancer: Uncovering clinical gaps in physician knowledge and approaches to clinical practice</td>
<td>E. Ovarian cancer Yelena Parada United Kingdom</td>
<td>all Congress dates</td>
<td>EPoster</td>
<td>all Congress dates</td>
<td>EPoster</td>
<td>EPoster</td>
</tr>
<tr>
<td>1104</td>
<td>Eight years survivors of advanced ovarian cancer</td>
<td>E. Ovarian cancer Davit Boltsha Germany</td>
<td>all Congress dates</td>
<td>EPoster</td>
<td>all Congress dates</td>
<td>EPoster</td>
<td>EPoster</td>
</tr>
<tr>
<td>1105</td>
<td>Can preoperative FDG PET/CT help to predict complete resection at primary cytoreductive surgery in highly pre-selected patients?</td>
<td>E. Ovarian cancer Felix Borja Spain</td>
<td>all Congress dates</td>
<td>EPoster</td>
<td>all Congress dates</td>
<td>EPoster</td>
<td>EPoster</td>
</tr>
<tr>
<td>1112</td>
<td>MiFAPs is related to ovarian cancer progression but not suitable as prognostic biomarker</td>
<td>E. Ovarian cancer Katarzyna Kajawa Poland</td>
<td>all Congress dates</td>
<td>EPoster</td>
<td>all Congress dates</td>
<td>EPoster</td>
<td>EPoster</td>
</tr>
<tr>
<td>1114</td>
<td>BRCA1, BRCA2 mutation in high grade ovarian cancers, fallopian tube cancer, primary peritoneal carcinoma</td>
<td>E. Ovarian cancer Hanna Trubhan Belarus</td>
<td>all Congress dates</td>
<td>EPoster</td>
<td>all Congress dates</td>
<td>EPoster</td>
<td>EPoster</td>
</tr>
<tr>
<td>1117</td>
<td>Recycling of discarded Ovarian Cancer ASCites to monitor therapy resistance</td>
<td>E. Ovarian cancer Sara Ricardo Portugal</td>
<td>all Congress dates</td>
<td>EPoster</td>
<td>all Congress dates</td>
<td>EPoster</td>
<td>EPoster</td>
</tr>
<tr>
<td>1119</td>
<td>Burdened family history in Patients with Ovarian Cancer: Retrospective Mono-centric Study</td>
<td>E. Ovarian cancer Hanna Trubhan Belarus</td>
<td>all Congress dates</td>
<td>EPoster</td>
<td>all Congress dates</td>
<td>EPoster</td>
<td>EPoster</td>
</tr>
<tr>
<td>1149</td>
<td>Methylatin-based treatments are currently a valid therapeutic option in heavily pretreated ovarian cancer patients with hypersensitivity reactions (HRs) to carboplatin in the antiangiogenic context</td>
<td>E. Ovarian cancer Arancazu Manzano Spain</td>
<td>all Congress dates</td>
<td>EPoster</td>
<td>all Congress dates</td>
<td>EPoster</td>
<td>EPoster</td>
</tr>
<tr>
<td>1156</td>
<td>Validation of peritoneal cancer index (PCI) score as a non-invasive tool for surgical resectability in advanced ovarian cancer patients in a tertiary care center of Pakistan.</td>
<td>E. Ovarian cancer Humaira Aziz Pakistan</td>
<td>all Congress dates</td>
<td>EPoster</td>
<td>all Congress dates</td>
<td>EPoster</td>
<td>EPoster</td>
</tr>
<tr>
<td>1157</td>
<td>Is still possible to treat ovarian cancer in a district general hospital? - reflections from our experience</td>
<td>E. Ovarian cancer Claudia Casanova Italy</td>
<td>all Congress dates</td>
<td>EPoster</td>
<td>all Congress dates</td>
<td>EPoster</td>
<td>EPoster</td>
</tr>
<tr>
<td>1222</td>
<td>Germ Cell Tumours: Relevance of Prompt Diagnosis</td>
<td>E. Ovarian cancer Felicia Elena Bursuina United Kingdom</td>
<td>all Congress dates</td>
<td>EPoster</td>
<td>all Congress dates</td>
<td>EPoster</td>
<td>EPoster</td>
</tr>
<tr>
<td>1225</td>
<td>Correlation between the immunocytochemistry of the fallopian tube cells and the pathological findings of the contralateral ovary</td>
<td>E. Ovarian cancer Sofia Lalka Greece</td>
<td>all Congress dates</td>
<td>EPoster</td>
<td>all Congress dates</td>
<td>EPoster</td>
<td>EPoster</td>
</tr>
<tr>
<td>1243</td>
<td>Anxiety and post-traumatic stress disorder in women referred after symptom triggered testing for ovarian cancer - analysis from the large multicentre national UK ROCkS study</td>
<td>E. Ovarian cancer Audrey Keong United Kingdom</td>
<td>all Congress dates</td>
<td>EPoster</td>
<td>all Congress dates</td>
<td>EPoster</td>
<td>EPoster</td>
</tr>
<tr>
<td>1255</td>
<td>Histopathological features and treatment outcomes of ovarian clear cell carcinoma: the Pan-Birmingham Ovarian Cancer Centre experience</td>
<td>E. Ovarian cancer Fong-Lien Audrey Keong United Kingdom</td>
<td>all Congress dates</td>
<td>EPoster</td>
<td>all Congress dates</td>
<td>EPoster</td>
<td>EPoster</td>
</tr>
<tr>
<td>1256</td>
<td>PRELIMINARY DATA ABOUT CORRELATION BETWEEN CA125 AND METABOLIC MARKERS IN ADVANCED OVARIAN CANCER</td>
<td>E. Ovarian cancer Marlene Lee Germany</td>
<td>all Congress dates</td>
<td>EPoster</td>
<td>all Congress dates</td>
<td>EPoster</td>
<td>EPoster</td>
</tr>
<tr>
<td>1258</td>
<td>FRA Experiences of Implementing Enhanced Recovery After Surgery (ERAS) at two German ESGO Centers of Excellence - KORE-INNOVATION: the First Prospective Clinical Trial to assess a Multicentre, Open-Label Phase 1/2 Trial Evaluating the Safety, Tolerability, and Efficacy of MORAH-202, a Folate Receptor Alpha-H</td>
<td>E. Ovarian cancer Marlene Lee Germany</td>
<td>all Congress dates</td>
<td>EPoster</td>
<td>all Congress dates</td>
<td>EPoster</td>
<td>EPoster</td>
</tr>
<tr>
<td>1267</td>
<td>FRA Experiences of Implementing Enhanced Recovery After Surgery (ERAS) at two German ESGO Centers of Excellence - KORE-INNOVATION: the First Prospective Clinical Trial to assess a Multicentre, Open-Label Phase 1/2 Trial Evaluating the Safety, Tolerability, and Efficacy of MORAH-202, a Folate Receptor Alpha-Human Anti-cancer Antibody-Derived Conjugate in Patients With Selected</td>
<td>E. Ovarian cancer Massoor Mirza Denmark</td>
<td>all Congress dates</td>
<td>EPoster</td>
<td>all Congress dates</td>
<td>EPoster</td>
<td>EPoster</td>
</tr>
<tr>
<td>1274</td>
<td>PRELIMINARY DATA ABOUT CORRELATION BETWEEN CA125 AND METABOLIC MARKERS IN ADVANCED OVARIAN CANCER TREATED WITH MAINTENANCE PARP INHIBitors.</td>
<td>E. Ovarian cancer Giulia Sabetta Italy</td>
<td>all Congress dates</td>
<td>EPoster</td>
<td>all Congress dates</td>
<td>EPoster</td>
<td>EPoster</td>
</tr>
<tr>
<td>1287</td>
<td>Case Report of a patient with relapsed ovarian cancer and therapy with all three approved PARP inhibitors</td>
<td>E. Ovarian cancer Katharina Keller Germany</td>
<td>all Congress dates</td>
<td>EPoster</td>
<td>all Congress dates</td>
<td>EPoster</td>
<td>EPoster</td>
</tr>
<tr>
<td>ID</td>
<td>Title</td>
<td>Authors</td>
<td>Country</td>
<td>Type</td>
<td>Dates</td>
<td>Venue</td>
<td></td>
</tr>
<tr>
<td>----------</td>
<td>----------------------------------------------------------------------</td>
<td>-------------------</td>
<td>------------</td>
<td>----------</td>
<td>-------------</td>
<td>---------------</td>
<td></td>
</tr>
<tr>
<td>1288</td>
<td>Unknown ovarian neoplasm with retroperitoneal involvement - Metastasis or two primary tumors? - Case report</td>
<td>E. Ovarian cancer</td>
<td>Archil</td>
<td>Sharashenidze</td>
<td>Georgia</td>
<td>ePoster</td>
<td></td>
</tr>
<tr>
<td>1312</td>
<td>Feasibility of carboplatin monotherapy versus carboplatin-paclitaxel in frail elderly epithelial ovarian cancer patients</td>
<td>E. Ovarian cancer</td>
<td>Tamara</td>
<td>Yu</td>
<td>United Kingdom</td>
<td>ePoster</td>
<td></td>
</tr>
<tr>
<td>1313</td>
<td>Clinical Significance of Her2/Neu, Muc1, Estrogen and Progesterone Receptor Expression In Malignant Epithelial Ovarian Tumors</td>
<td>E. Ovarian cancer</td>
<td>Uzun</td>
<td>Karabuklu Gulec</td>
<td>Turkey</td>
<td>ePoster</td>
<td></td>
</tr>
<tr>
<td>1326</td>
<td>Interval disease surgery by robotic approach in ovarian cancer</td>
<td>E. Ovarian cancer</td>
<td>Carlos</td>
<td>Ortega</td>
<td>Spain</td>
<td>ePoster</td>
<td></td>
</tr>
<tr>
<td>1329</td>
<td>Ovarian cancer hospitalization rates during the COVID-19 pandemic: is the state of Sao Paulo and its correlation with pandemic-related variables</td>
<td>E. Ovarian cancer</td>
<td>Francisco</td>
<td>Candido dos Reis</td>
<td>Brazil</td>
<td>ePoster</td>
<td></td>
</tr>
<tr>
<td>1336</td>
<td>DIFFERENCES IN EPIDEMIOLOGY, CLINICAL FEATURES AND PROGNOSIS OF EOC IN ARAB WOMEN AS COMPARED WITH JEWISH WOMEN IN NORTHERN ISRAEL</td>
<td>E. Ovarian cancer</td>
<td>Inbar</td>
<td>Ben Sharach</td>
<td>Israel</td>
<td>ePoster</td>
<td></td>
</tr>
<tr>
<td>1348</td>
<td>Role of Computed Tomography (CT) scan based reporting system “PAUSE” to predict surgical resectability in Epithelial Ovarian Cancer</td>
<td>E. Ovarian cancer</td>
<td>Seema</td>
<td>Singhil</td>
<td>India</td>
<td>ePoster</td>
<td></td>
</tr>
<tr>
<td>1349</td>
<td>Treated as a skin carcinoma: recurrent, metastatic squamous cell carcinoma from a degenerated mature teratoma of the ovary</td>
<td>E. Ovarian cancer</td>
<td>Apostolos</td>
<td>Sarvallassis</td>
<td>Switzerland</td>
<td>ePoster</td>
<td></td>
</tr>
<tr>
<td>1356</td>
<td>Epithelial ovarian cancer and brain metastases: survival analysis according to the BRCA status</td>
<td>E. Ovarian cancer</td>
<td>Carolina Maria</td>
<td>Saissu</td>
<td>Italy</td>
<td>ePoster</td>
<td></td>
</tr>
<tr>
<td>1375</td>
<td>Minimally invasive vs. open interval debulking surgery in advanced ovarian cancer patients: pattern of recurrence and oncological outcome in a propensity matched population</td>
<td>E. Ovarian cancer</td>
<td>Camillone</td>
<td>Conte</td>
<td>Italy</td>
<td>ePoster</td>
<td></td>
</tr>
<tr>
<td>1402</td>
<td>Implementing HRD testing in routine clinical practice among patients with high grade advanced ovarian cancer.</td>
<td>E. Ovarian cancer</td>
<td>Florian</td>
<td>Heitz</td>
<td>Germany</td>
<td>ePoster</td>
<td></td>
</tr>
<tr>
<td>1404</td>
<td>Indocyanine Green in Near-Infrared Light for Intra-Operative Imaging of Residual Ovarian Cancer after Neoadjuvant Chemotherapy. Initial Experience</td>
<td>E. Ovarian cancer</td>
<td>Paul</td>
<td>Kubeslak</td>
<td>Romania</td>
<td>ePoster</td>
<td></td>
</tr>
<tr>
<td>1406</td>
<td>A Review of Ovarian Cancer in Northern Ireland: A Retrospective Cohort Study</td>
<td>E. Ovarian cancer</td>
<td>Josh</td>
<td>McMullan</td>
<td>United Kingdom</td>
<td>ePoster</td>
<td></td>
</tr>
<tr>
<td>1409</td>
<td>ETPICAL PROLIFERATIVE CLEAR CELL TUMOR ORIGINATED IN ENDOMETRIOSIS OF THE ABDOMINAL WALL</td>
<td>E. Ovarian cancer</td>
<td>Dianelle</td>
<td>Sito Troya</td>
<td>Colombia</td>
<td>ePoster</td>
<td></td>
</tr>
<tr>
<td>1412</td>
<td>The association between social deprivation in Northern Ireland and treatment of ovarian cancer</td>
<td>E. Ovarian cancer</td>
<td>Josh</td>
<td>McMullan</td>
<td>United Kingdom</td>
<td>ePoster</td>
<td></td>
</tr>
<tr>
<td>1428</td>
<td>Safety of interval debulking surgery in patients with malignant ascites from ovarian cancer: Results from the prospective, randomised ATLANTIS trial</td>
<td>E. Ovarian cancer</td>
<td>Roca Angelica</td>
<td>Salcedo-</td>
<td>Mexico</td>
<td>ePoster</td>
<td></td>
</tr>
<tr>
<td>1438</td>
<td>Epithelial ovarian cancers during pregnancy: the results of a large retrospective study from the INCIP network</td>
<td>E. Ovarian cancer</td>
<td>Rita</td>
<td>Trozzi</td>
<td>Italy</td>
<td>ePoster</td>
<td></td>
</tr>
<tr>
<td>1450</td>
<td>Androgen metabolism and signalling in ovarian cancer</td>
<td>E. Ovarian cancer</td>
<td>Marija</td>
<td>Gjorgoska</td>
<td>Slovenia</td>
<td>ePoster</td>
<td></td>
</tr>
<tr>
<td>1451</td>
<td>CRITICAL CARE MANAGEMENT FOLLOWING CYTOREDUCTIVE SURGERY WITH HYPERTERMIC INTRAPERITONEAL CHEMOTHERAPY: NOT RECENTLY INDICATED</td>
<td>E. Ovarian cancer</td>
<td>W. J.</td>
<td>van Driel</td>
<td>Netherlands</td>
<td>ePoster</td>
<td></td>
</tr>
<tr>
<td>1453</td>
<td>Chemotherapy response score as a predictor of survival among patients undergoing interval debulking surgery for ovarian cancer</td>
<td>E. Ovarian cancer</td>
<td>Ioannis</td>
<td>Rodolakis</td>
<td>Greece</td>
<td>ePoster</td>
<td></td>
</tr>
<tr>
<td>1459</td>
<td>Malignant struma ovarii in an asymptomatic multiparous 20-year-old patient: a case report</td>
<td>E. Ovarian cancer</td>
<td>Eleftherios G.</td>
<td>Kkonos</td>
<td>Greece</td>
<td>ePoster</td>
<td></td>
</tr>
<tr>
<td>1481</td>
<td>CYTOREDUCTIVE SURGERY IN ADVANCED OVARIAN CANCER PATIENTS</td>
<td>E. Ovarian cancer</td>
<td>Olga</td>
<td>Smitanova</td>
<td>Russian Federation</td>
<td>ePoster</td>
<td></td>
</tr>
<tr>
<td>1484</td>
<td>Characteristics, treatment patterns and outcomes of patients with newly diagnosed advanced ovarian cancer (aOC) in England</td>
<td>E. Ovarian cancer</td>
<td>Angela</td>
<td>Whittle</td>
<td>United Kingdom</td>
<td>ePoster</td>
<td></td>
</tr>
<tr>
<td>1493</td>
<td>Recurrence in Ovarian Cancer after cytoreductive surgery according to the type of chemotherapy</td>
<td>E. Ovarian cancer</td>
<td>Maria</td>
<td>Pellise Tirone</td>
<td>Spain</td>
<td>ePoster</td>
<td></td>
</tr>
<tr>
<td>1495</td>
<td>Differential metabolism of estrogens in model cell lines and tissues of HGSOX subtypes</td>
<td>E. Ovarian cancer</td>
<td>Renata</td>
<td>Pavlic</td>
<td>Slovenia</td>
<td>ePoster</td>
<td></td>
</tr>
<tr>
<td>1517</td>
<td>Winlow Comprehensive Cancer Centre 100 months experience in cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with peritoneal disease</td>
<td>E. Ovarian cancer</td>
<td>Marcin</td>
<td>Jarekya</td>
<td>Poland</td>
<td>ePoster</td>
<td></td>
</tr>
<tr>
<td>1524</td>
<td>Do epigenetic and endophytic patterns in borderline ovarian tumors have different prognostic implications? A large multicentric experience</td>
<td>E. Ovarian cancer</td>
<td>Vito Andrea</td>
<td>Capozzi</td>
<td>Italy</td>
<td>ePoster</td>
<td></td>
</tr>
<tr>
<td>1527</td>
<td>Reliability of IOTA Adnex Model in Borderline Ovarian Tumors, A Single Center Study</td>
<td>E. Ovarian cancer</td>
<td>Humaira</td>
<td>Aziz</td>
<td>Pakistan</td>
<td>ePoster</td>
<td></td>
</tr>
<tr>
<td>1528</td>
<td>Carcinoid tumors of the ovary, a rare neoplasm: description of cases and review of literature</td>
<td>E. Ovarian cancer</td>
<td>Marta</td>
<td>Hervas Garcia</td>
<td>Spain</td>
<td>ePoster</td>
<td></td>
</tr>
<tr>
<td>1540</td>
<td>MRI VS 2D Randomized, Molecular Driven Phase II Trial of Carboplatin-Paclitaxel-Bevacizumab vs Carboplatin-Paclitaxel-Bevacizumab vs Carboplatin-Paclitaxel-Rucaparib</td>
<td>E. Ovarian cancer</td>
<td>Lucia</td>
<td>Musacchio</td>
<td>Italy</td>
<td>ePoster</td>
<td></td>
</tr>
<tr>
<td>1552</td>
<td>Survival after Hyperthermic Intraperitoneal Chemotherapy in Kazakhstani women with ovarian cancer: KazOR experience</td>
<td>E. Ovarian cancer</td>
<td>Alina</td>
<td>Satanova</td>
<td>Kazakhstan</td>
<td>ePoster</td>
<td></td>
</tr>
<tr>
<td>1557</td>
<td>Renatrectic lymph node involvement in patients undergoing a bowel resection during debulking surgery in advanced ovarian cancer</td>
<td>E. Ovarian cancer</td>
<td>Federica</td>
<td>Galli</td>
<td>Italy</td>
<td>ePoster</td>
<td></td>
</tr>
<tr>
<td>ID</td>
<td>Title</td>
<td>Category</td>
<td>Authors</td>
<td>Country</td>
<td>Type</td>
<td>Congress Dates</td>
<td>Exhibit Area</td>
</tr>
<tr>
<td>------</td>
<td>----------------------------------------------------------------------</td>
<td>----------------------------</td>
<td>--------------------------</td>
<td>-------------</td>
<td>-----------</td>
<td>----------------</td>
<td>----------------------</td>
</tr>
<tr>
<td>1589</td>
<td>Gynecomammary cancer in young adults, about 8 cases and a literature review</td>
<td>8. Pathology</td>
<td>Jihad Abbou</td>
<td>Morocco</td>
<td>ePoster</td>
<td>all</td>
<td>ePoster kiosk (Exhibit Area)</td>
</tr>
<tr>
<td>246</td>
<td>Influence of Depth of Excision on Test of Cure Following Loop Excisional Treatment for High Grade CIN</td>
<td>9. Prevention of gynaecologic cancer</td>
<td>Melin Dokmeci</td>
<td>United Kingdom</td>
<td>ePoster</td>
<td>all</td>
<td>ePoster kiosk (Exhibit Area)</td>
</tr>
<tr>
<td>631</td>
<td>The Impact of COVID 19 on Cervical Cancer Screening and Triage</td>
<td>9. Prevention of gynaecologic cancer</td>
<td>Jessica Velasquez</td>
<td>United States</td>
<td>ePoster</td>
<td>all</td>
<td>ePoster kiosk (Exhibit Area)</td>
</tr>
<tr>
<td>675</td>
<td>Awareness, knowledge and attitudes on primary and secondary prevention of cervical cancer: a survey study</td>
<td>9. Prevention of gynaecologic cancer</td>
<td>Vasilios Pergialiotis</td>
<td>Greece</td>
<td>ePoster</td>
<td>all</td>
<td>ePoster kiosk (Exhibit Area)</td>
</tr>
<tr>
<td>679</td>
<td>Prevalence of HPV infection among young women in Almaty, Kazakhstan</td>
<td>9. Prevention of gynaecologic cancer</td>
<td>Alma Satanova</td>
<td>Kazakhstan</td>
<td>ePoster</td>
<td>all</td>
<td>ePoster kiosk (Exhibit Area)</td>
</tr>
<tr>
<td>694</td>
<td>Hereditary cancer predisposition in Brazilian public health system: is it possible to identify?</td>
<td>9. Prevention of gynaecologic cancer</td>
<td>Vandré Carneiro</td>
<td>Brazil</td>
<td>ePoster</td>
<td>all</td>
<td>ePoster kiosk (Exhibit Area)</td>
</tr>
<tr>
<td>1049</td>
<td>Patients with TP53 mutation followed up in a hereditary gynaecological cancer unit</td>
<td>9. Prevention of gynaecologic cancer</td>
<td>Juan Manuel Pina Moreno</td>
<td>Spain</td>
<td>ePoster</td>
<td>all</td>
<td>ePoster kiosk (Exhibit Area)</td>
</tr>
<tr>
<td>1116</td>
<td>Barriers in the cervical cancer screening program and how self-sampling for HPV-testing is experienced as a solution to them</td>
<td>9. Prevention of gynaecologic cancer</td>
<td>Eva Payrich</td>
<td>Germany</td>
<td>ePoster</td>
<td>all</td>
<td>ePoster kiosk (Exhibit Area)</td>
</tr>
<tr>
<td>1169</td>
<td>Germline genetic test for ovarian cancer: is it important to be available?</td>
<td>9. Prevention of gynaecologic cancer</td>
<td>Vandré Carneiro</td>
<td>Brazil</td>
<td>ePoster</td>
<td>all</td>
<td>ePoster kiosk (Exhibit Area)</td>
</tr>
<tr>
<td>1179</td>
<td>EFFECTIVENESS OF A MULTI-INGREDIENT CORIOLUS VERSICOLOR-BASED VAGINAL GEL IN HPV+ and HIV+ PATIENTS: A PILOT OBSERVATIONAL STUDY</td>
<td>9. Prevention of gynaecologic cancer</td>
<td>Jesús Joaquín Hijona</td>
<td>Spain</td>
<td>ePoster</td>
<td>all</td>
<td>ePoster kiosk (Exhibit Area)</td>
</tr>
<tr>
<td>1190</td>
<td>A conservative treatment of CIN II using a Coriolus versicolor-based vaginal gel: an observational study</td>
<td>9. Prevention of gynaecologic cancer</td>
<td>Silvia Herrero Barrios</td>
<td>Spain</td>
<td>ePoster</td>
<td>all</td>
<td>ePoster kiosk (Exhibit Area)</td>
</tr>
<tr>
<td>1191</td>
<td>EFFICACY OF A MULTI-INGREDIENT CORIOLUS VERSICOLOR-BASED VAGINAL GEL IN HIGH-RISK HPV WOMEN OVER 40: SUB-ANALYSIS OF THE PALOMA CLINICAL TRIAL &amp; PAPILOBS REAL-LIFE STUDY</td>
<td>9. Prevention of gynaecologic cancer</td>
<td>Yann Guzlın</td>
<td>Spain</td>
<td>ePoster</td>
<td>all</td>
<td>ePoster kiosk (Exhibit Area)</td>
</tr>
<tr>
<td>1411</td>
<td>The impact of COVID19 on the Cervical Screening Programme and Colposcopy Services in Northern Ireland</td>
<td>9. Prevention of gynaecologic cancer</td>
<td>Josh McMullan</td>
<td>United Kingdom</td>
<td>ePoster</td>
<td>all</td>
<td>ePoster kiosk (Exhibit Area)</td>
</tr>
<tr>
<td>1554</td>
<td>Patients with PALB2 mutation followed up in a hereditary gynaecological cancer unit</td>
<td>9. Prevention of gynaecologic cancer</td>
<td>Juan Manuel Pina Moreno</td>
<td>Spain</td>
<td>ePoster</td>
<td>all</td>
<td>ePoster kiosk (Exhibit Area)</td>
</tr>
<tr>
<td>1566</td>
<td>Cytology and HPV Testing in Cervical Cancer Screening: Factors Determining Persistence and Clearance</td>
<td>9. Prevention of gynaecologic cancer</td>
<td>Ahmet Baris Guzeli</td>
<td>Turkey</td>
<td>ePoster</td>
<td>all</td>
<td>ePoster kiosk (Exhibit Area)</td>
</tr>
<tr>
<td>1681</td>
<td>BACTERIAL VAGINOSIS AND HPV-RELATED CERVICAL LESIONS</td>
<td>9. Prevention of gynaecologic cancer</td>
<td>Iryna Marysina</td>
<td>Ukraine</td>
<td>ePoster</td>
<td>all</td>
<td>ePoster kiosk (Exhibit Area)</td>
</tr>
</tbody>
</table>